Skip to content
2000
image of Microalbuminuria as a Prognostic Marker in Essential Hypertension

Abstract

Essential hypertension is a major cardiovascular pathology globally, with an estimated prevalence of approximately 33%, and it is a significant contributor to both mortality and adverse cardiovascular events. Finding early prognostic markers in such individuals could, thus, provide enhanced risk stratification and identification of patients with higher odds of target-organ damage or adverse events. Microalbuminuria is defined as an abnormal excretion of albumin in urine, is well associated with vascular disease, endothelial dysfunction, and low-grade inflammation, and is a marker of subclinical renal damage. Through the years, microalbuminuria at baseline has been well correlated with increasing blood pressure levels and blood pressure patterns, , non-dipping phenotype. At the same time, its presence in hypertensive individuals indicated increased rates of mortality, renal disease progression, and major adverse cardiovascular outcomes, including stroke and myocardial infarction. Thus, microalbuminuria can provide a prognostic marker of future adverse events in hypertensive individuals. Interestingly, standard antihypertensive pharmacotherapy and newer drugs have shown regression of microalbuminuria extent and renoprotection in both diabetic as well as hypertensive individuals, implying that early therapy could decrease the rate of disease progression and limit target-organ damage. Thus, the aim of this review is to analyze the available studies documenting the predictive role of microalbuminuria for both mortality, target-organ damage, and adverse events, as well as describe the impact of pharmacotherapy in the presence and extent of subclinical renal damage, as shown by the levels of this marker.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673348953250310044927
2025-03-25
2025-09-09

  • From This Site

    /content/journals/cmc/10.2174/0109298673348953250310044927
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ferrari A.J. Santomauro D.F. Aali A. Abate Y.H. Abbafati C. Abbastabar H. Abd ElHafeez S. Abdelmasseh M. Abd-Elsalam S. Abdollahi A. Abdullahi A. Abegaz K.H. Zuñiga R.A.A. Aboagye R.G. Abolhassani H. Abreu L.G. Abualruz H. Abu-Gharbieh E. Abu-Rmeileh N.M.E. Ackerman I.N. Addo I.Y. Addolorato G. Adebiyi A.O. Adepoju A.V. Adewuyi H.O. Afyouni S. Afzal S. Afzal S. Agodi A. Ahmad A. Ahmad D. Ahmad F. Ahmad S. Ahmed A. Ahmed L.A. Ahmed M.B. Ajami M. Akinosoglou K. Akkaif M.A. Al Hasan S.M. Alalalmeh S.O. Al-Aly Z. Albashtawy M. Aldridge R.W. Alemu M.D. Alemu Y.M. Alene K.A. Al-Gheethi A.A.S. Alharrasi M. Alhassan R.K. Ali M.U. Ali R. Ali S.S.S. Alif S.M. Aljunid S.M. Al-Marwani S. Almazan J.U. Alomari M.A. Al-Omari B. Altaany Z. Alvis-Guzman N. Alvis-Zakzuk N.J. Alwafi H. Al-Wardat M.S. Al-Worafi Y.M. Aly S. Alzoubi K.H. Amare A.T. Amegbor P.M. Ameyaw E.K. Amin T.T. Amindarolzarbi A. Amiri S. Amugsi D.A. Ancuceanu R. Anderlini D. Anderson D.B. Andrade P.P. Andrei C.L. Ansari H. Antony C.M. Anwar S. Anwar S.L. Anwer R. Anyanwu P.E. Arab J.P. Arabloo J. Arafat M. Araki D.T. Aravkin A.Y. Arkew M. Armocida B. Arndt M.B. Arooj M. Artamonov A.A. Aruleba R.T. Arumugam A. Ashbaugh C. Ashemo M.Y. Ashraf M. Asika M.O. Askari E. Astell-Burt T. Athari S.S. Atorkey P. Atout M.M.W. Atreya A. Aujayeb A. Ausloos M. Avan A. Awotidebe A.W. Awuviry-Newton K. Ayala Quintanilla B.P. Ayuso-Mateos J.L. Azadnajafabad S. Azevedo R.M.S. Babu A.S. Badar M. Badiye A.D. Baghdadi S. Bagheri N. Bah S. Bai R. Baker J.L. Bakkannavar S.M. Bako A.T. Balakrishnan S. Bam K. Banik P.C. Barchitta M. Bardhan M. Bardideh E. Barker-Collo S.L. Barqawi H.J. Barrow A. Barteit S. Barua L. Bashiri Aliabadi S. Basiru A. Basu S. Basu S. Bathini P.P. Batra K. Baune B.T. Bayileyegn N.S. Behnam B. Behnoush A.H. Beiranvand M. Bejarano Ramirez D.F. Bell M.L. Bello O.O. Beloukas A. Bensenor I.M. Berezvai Z. Bernabe E. Bernstein R.S. Bettencourt P.J.G. Bhagavathula A.S. Bhala N. Bhandari D. Bhargava A. Bhaskar S. Bhat V. Bhatti G.K. Bhatti J.S. Bhatti M.S. Bhatti R. Bhutta Z.A. Bikbov B. Bishai J.D. Bisignano C. Bitra V.R. Bjørge T. Bodolica V. Bodunrin A.O. Bogale E.K. Bonakdar Hashemi M. Bonny A. Bora Basara B. Borhany H. Boxe C. Brady O.J. Bragazzi N.L. Braithwaite D. Brant L.C. Brauer M. Breitner S. Brenner H. Brown J. Brugha T. Bulamu N.B. Buonsenso D. Burkart K. Burns R.A. Busse R. Bustanji Y. Butt Z.A. Byun J. Caetano dos Santos F.L. Calina D. Cámera L.A. Campos-Nonato I.R. Cao C. Capodici A. Carr S. Carreras G. Carugno A. Carvalho M. Castaldelli-Maia J.M. Castañeda-Orjuela C.A. Castelpietra G. Catapano A.L. Cattaruzza M.S. Caye A. Cegolon L. Cembranel F. Cenderadewi M. Cerin E. Chakraborty P.A. Chan J.S.K. Chan R.N.C. Chandika R.M. Chandrasekar E.K. Charalampous P. Chattu V.K. Chatzimavridou-Grigoriadou V. Chen A.W. Chen A-T. Chen C.S. Chen H. Chen N.M. Cheng E.T.W. Chimed-Ochir O. Chimoriya R. Ching P.R. Cho W.C.S. Choi S. Chong B. Chong Y.Y. Choudhari S.G. Chowdhury R. Christensen S.W.M.P. Chu D-T. Chukwu I.S. Chung E. Chung E. Chutiyami M. Claassens M.M. Cogen R.M. Columbus A. Conde J. Cortesi P.A. Cousin E. Criqui M.H. Cruz-Martins N. Dadras O. Dai S. Dai X. Dai Z. Dalaba M.A. Damiani G. Das J.K. Das S. Dashti M. Dávila-Cervantes C.A. Davletov K. De Leo D. Debele A.T. Debopadhaya S. DeCleene N.K. Deeba F. Degenhardt L. Del Bo’ C. Delgado-Enciso I. Demetriades A.K. Denova-Gutiérrez E. Dervenis N. Desai H.D. Desai R. Deuba K. Dhama K. Dharmaratne S.D. Dhingra S. Dias da Silva D. Diaz D. Diaz L.A. Diaz M.J. Dima A. Ding D.D. Dirac M.A. Do T.H.P. do Prado C.B. Dohare S. Dominguez R-M.V. Dong W. Dongarwar D. D’Oria M. Dorsey E.R. Doshmangir L. Dowou R.K. Driscoll T.R. Dsouza H.L. Dsouza V. Dube J. Dumith S.C. Duncan B.B. Duraes A.R. Duraisamy S. Durojaiye O.C. Dzianach P.A. Dziedzic A.M. Eboreime E. Ebrahimi A. Edinur H.A. Edvardsson D. Eikemo T.A. Eini E. Ekholuenetale M. Ekundayo T.C. El Sayed I. El Tantawi M. Elbarazi I. Elemam N.M. ElGohary G.M.T. Elhadi M. Elmeligy O.A.A. ELNahas G. Elshaer M. Elsohaby I. Engelbert Bain L. Erkhembayar R. Eshrati B. Estep K. Fabin N. Fagbamigbe A.F. Falzone L. Fareed M. Farinha C.S.S. Faris M.A.I.E.M. Faro A. Farrokhi P. Fatehizadeh A. Fauk N.K. Feigin V.L. Feng X. Fereshtehnejad S-M. Feroze A.H. Ferreira N. Ferreira P.H. Fischer F. Flavel J. Flood D. Flor L.S. Foigt N.A. Folayan M.O. Force L.M. Fortuna D. Foschi M. Franklin R.C. Freitas A. Fukumoto T. Furtado J.M. Gaal P.A. Gadanya M.A. Gaidhane A.M. Gaihre S. Galali Y. Ganbat M. Gandhi A.P. Ganesan B. Ganie M.A. Ganiyani M.A. Gardner W.M. Gebi T.G. Gebregergis M.W. Gebrehiwot M. Gebremariam T.B.B. Gebremeskel T.G. Gela Y.Y. Georgescu S.R. Getachew Obsa A. Gething P.W. Getie M. Ghadiri K. Ghadirian F. Ghailan K.Y. Ghajar A. Ghasemi M.R. Ghasempour Dabaghi G. Ghasemzadeh A. Ghazy R.M. Gholamrezanezhad A. Ghorbani M. Ghotbi E. Gibson R.M. Gill T.K. Ginindza T.G. Girmay A. Glasbey J.C. Göbölös L. Godinho M.A. Goharinezhad S. Goldust M. Golechha M. Goleij P. Gona P.N. Gorini G. Goulart A.C. Grada A. Grivna M. Guan S-Y. Guarducci G. Gubari M.I.M. Gudeta M.D. Guha A. Guicciardi S. Gulati S. Gulisashvili D. Gunawardane D.A. Guo C. Gupta A.K. Gupta B. Gupta I. Gupta M. Gupta R. Gupta V.B. Gupta V.K. Gupta V.K. Gutiérrez R.A. Habibzadeh F. Habibzadeh P. Haddadi R. Hadi N.R. Haep N. Hafezi-Nejad N. Hafiz A. Hagins H. Halboub E.S. Halimi A. Haller S. Halwani R. Hamilton E.B. Hankey G.J. Hannan M.A. Haque M.N. Harapan H. Haro J.M. Hartvigsen J. Hasaballah A.I. Hasan I. Hasanian M. Hasnain M.S. Hassan A. Haubold J. Havmoeller R.J. Hay S.I. Hayat K. Hebert J.J. Hegazi O.E. Heidari G. Helfer B. Hemmati M. Hendrie D. Henson C.A. Hezam K. Hiraike Y. Hoan N.Q. Holla R. Hon J. Hossain M.M. Hosseinzadeh H. Hosseinzadeh M. Hostiuc M. Hostiuc S. Hsu J.M. Huang J. Hugo F.N. Hushmandi K. Hussain J. Hussein N.R. Huynh C.K. Huynh H-H. Hwang B-F. Iannucci V.C. Ihler A.L. Ikiroma A.I. Ikuta K.S. Ilesanmi O.S. Ilic I.M. Ilic M.D. Imam M.T. Immurana M. Irham L.M. Islam M.R. Islam S.M.S. Islami F. Ismail F. Ismail N.E. Isola G. Iwagami M. Iwu C.C.D. Iyer M. Jaafari J. Jacobsen K.H. Jadidi-Niaragh F. Jafarinia M. Jaggi K. Jahankhani K. Jahanmehr N. Jahrami H. Jain A. Jain N. Jairoun A.A. Jaiswal A. Jakovljevic M. Jatau A.I. Javadov S. Javaheri T. Jayapal S.K. Jayaram S. Jee S.H. Jeganathan J. Jeyakumar A. Jha A.K. Jiang H. Jin Y. Jonas J.B. Joo T. Joseph A. Joseph N. Joshua C.E. Jozwiak J.J. Jürisson M. K V. Kaambwa B. Kabir A. Kabir Z. Kadashetti V. Kalani R. Kalankesh L.R. Kaliyadan F. Kalra S. Kamenov K. Kamyari N. Kanagasabai T. Kandel H. Kanmanthareddy A.R. Kanmodi K.K. Kantar R.S. Karaye I.M. Karim A. Karimi S.E. Karimi Y. Kasraei H. Kassel M.B. Kauppila J.H. Kawakami N. Kayode G.A. Kazemi F. Kazemian S. Keikavoosi-Arani L. Keller C. Kempen J.H. Kerr J.A. Keshtkar K. Kesse-Guyot E. Keykhaei M. Khajuria H. Khalaji A. Khalid A. Khalid N. Khalilian A. Khamesipour F. Khan A. Khan I. Khan M. Khan M.A.B. Khanmohammadi S. Khatab K. Khatami F. Khatatbeh M.M. Khater A.M. Khayat Kashani H.R. Khidri F.F. Khodadoust E. Khormali M. Khorrami Z. Kifle Z.D. Kim M.S. Kimokoti R.W. Kisa A. Kisa S. Knudsen A.K.S. Kocarnik J.M. Kochhar S. Koh H.Y. Kolahi A-A. Kompani F. Koren G. Korzh O. Kosen S. Koulmane Laxminarayana S.L. Krishan K. Krishna V. Krishnamoorthy V. Kuate Defo B. Kuddus M.A. Kuddus M. Kuitunen I. Kulkarni V. Kumar M. Kumar N. Kumar R. Kurmi O.P. Kusuma D. Kyu H.H. La Vecchia C. Lacey B. Ladan M.A. Laflamme L. Lafranconi A. Lahariya C. Lai D.T.C. Lal D.K. Lalloo R. Lallukka T. Lám J. Lan Q. Lan T. Landires I. Lanfranchi F. Langguth B. Laplante-Lévesque A. Larijani B. Larsson A.O. Lasrado S. Lauriola P. Le H-H. Le L.K.D. Le N.H.H. Le T.D.T. Leasher J.L. Ledda C. Lee M. Lee P.H. Lee S. Lee S.W. Lee W-C. Lee Y.H. LeGrand K.E. Lenzi J. Leong E. Leung J. Li M-C. Li W. Li X. Li Y. Li Y. Lim L-L. Lim S.S. Lindstrom M. Linn S. Liu G. Liu R. Liu S. Liu W. Liu X. Liu X. Llanaj E. Lo C-H. López-Bueno R. Loreche A.M. Lorenzovici L. Lozano R. Lubinda J. Lucchetti G. Lunevicius R. Lusk J.B. lv Ma Z.F. Machairas N. Madureira-Carvalho Á.M. Magaña Gómez J.A. Maghazachi A.A. Maharjan P. Mahasha P.W. Maheri M. Mahjoub S. Mahmoud M.A. Mahmoudi E. Majeed A. Makris K.C. Malakan Rad E. Malhotra K. Malik A.A. Malik I. Malta D.C. Manla Y. Mansour A. Mansouri P. Mansournia M.A. Mantilla Herrera A.M. Mantovani L.G. Manu E. Marateb H.R. Mardi P. Martinez G. Martinez-Piedra R. Martini D. Martins-Melo F.R. Martorell M. Marx W. Maryam S. Marzo R.R. Mathangasinghe Y. Mathieson S. Mathioudakis A.G. Mattumpuram J. Maugeri A. Mayeli M. Mazidi M. Mazzotti A. McGrath J.J. McKee M. McKowen A.L.W. McPhail M.A. Mehrabani-Zeinabad K. Mehrabi Nasab E. Mekene Meto T. Mendoza W. Menezes R.G. Mensah G.A. Mentis A-F.A. Meo S.A. Meresa H.A. Meretoja A. Meretoja T.J. Mersha A.M. Mestrovic T. Mettananda K.C.D. Mettananda S. Michalek I.M. Miller P.A. Miller T.R. Mills E.J. Minh L.H.N. Mirijello A. Mirrakhimov E.M. Mirutse M.K. Mirza-Aghazadeh-Attari M. Mirzaei M. Mirzaei R. Misganaw A. Mishra A.K. Mitchell P.B. Mittal C. Moazen B. Moberg M.E. Mohamed J. Mohamed M.F.H. Mohamed N.S. Mohammadi E. Mohammadi S. Mohammed H. Mohammed S. Mohammed S. Mohr R.M. Mokdad A.H. Molinaro S. Momtazmanesh S. Monasta L. Mondello S. Moodi Ghalibaf A.A. Moradi M. Moradi Y. Moradi-Lakeh M. Moraga P. Morawska L. Moreira R.S. Morovatdar N. Morrison S.D. Morze J. Mosapour A. Mosser J.F. Mossialos E. Motappa R. Mougin V. Mouodi S. Mrejen M. Msherghi A. Mubarik S. Mueller U.O. Mulita F. Munjal K. Murillo-Zamora E. Murlimanju B.V. Mustafa G. Muthu S. Muzaffar M. Myung W. Nagarajan A.J. Naghavi P. Naik G.R. Nainu F. Nair S. Najmuldeen H.H.R. Nangia V. Naqvi A.A. Narayana A.I. Nargus S. Nascimento G.G. Nashwan A.J. Nasrollahizadeh A. Nasrollahizadeh A. Natto Z.S. Nayak B.P. Nayak V.C. Nduaguba S.O. Negash H. Negoi I. Negoi R.I. Nejadghaderi S.A. Nesbit O.D. Netsere H.B. Ng M. Nguefack-Tsague G. Ngunjiri J.W. Nguyen D.H. Nguyen H.Q. Niazi R.K. Nikolouzakis T.K. Nikoobar A. Nikoomanesh F. Nikpoor A.R. Nnaji C.A. Nnyanzi L.A. Noman E.A. Nomura S. Norrving B. Nri-Ezedi C.A. Ntaios G. Ntsekhe M. Nurrika D. Nzoputam C.I. Nzoputam O.J. Oancea B. Odetokun I.A. O’Donnell M.J. Oguntade A.S. Oguta J.O. Okati-Aliabad H. Okeke S.R. Okekunle A.P. Okonji O.C. Olagunju A.T. Olasupo O.O. Olatubi M.I. Oliveira G.M.M. Olufadewa I.I. Olusanya B.O. Olusanya J.O. Omar H.A. Omer G.L. Omonisi A.E.E. Onie S. Onwujekwe O.E. Ordak M. Orish V.N. Ortega-Altamirano D.V. Ortiz A. Ortiz-Brizuela E. Osman W.M.S. Ostroff S.M. Osuagwu U.L. Otoiu A. Otstavnov N. Otstavnov S.S. Ouyahia A. Ouyang G. Owolabi M.O. P A M.P. Padron-Monedero A. Padubidri J.R. Palicz T. Palladino C. Pan F. Pandi-Perumal S.R. Pangaribuan H.U. Panos G.D. Panos L.D. Pantea Stoian A.M. Pardhan S. Parikh R.R. Pashaei A. Pasovic M. Passera R. Patel J. Patel S.K. Patil S. Patoulias D. Patthipati V.S. Pawar S. Pazoki Toroudi H. Pease S.A. Peden A.E. Pedersini P. Peng M. Pensato U. Pepito V.C.F. Peprah E.K. Peprah P. Perdigão J. Pereira M.O. Perianayagam A. Perico N. Pesudovs K. Petermann-Rocha F.E. Petri W.A. Pham H.T. Philip A.K. Phillips M.R. Pigeolet M. Pigott D.M. Pillay J.D. Piracha Z.Z. Pirouzpanah S. Plass D. Plotnikov E. Poddighe D. Polinder S. Postma M.J. Pourtaheri N. Prada S.I. Pradhan P.M.S. Prakash V. Prasad M. Prates E.J.S. Priscilla T. Pritchett N. Puri P. Puvvula J. Qasim N.H. Qattea I. Qazi A.S. Qian G. Rabiee Rad M. Radhakrishnan R.A. Radhakrishnan V. Raeisi Shahraki H. Rafferty Q. Raggi A. Raghav P.R. Rahim M.J. Rahman M.M. Rahman M.H.U. Rahman M. Rahman M.A. Rahmani S. Rahmanian M. Rahmawaty S. Rajaa S. Ramadan M.M. Ramasamy S.K. Ramasubramani P. Ramazanu S. Rana K. Ranabhat C.L. Rancic N. Rane A. Rao C.R. Rao K. Rao M. Rao S.J. Rashidi M-M. Rathnaiah Babu G. Rauniyar S.K. Rawaf D.L. Rawaf S. Razo C. Reddy M.M.R.K. Redwan E.M.M. Reifels L. Reiner R.C. Jr Remuzzi G. Renzaho A.M.N. Reshmi B. Reyes L.F. Rezaei N. Rezaei N. Rezaei N. Rezaei Hachesu P. Rezaeian M. Rickard J. Rodrigues C.F. Rodriguez J.A.B. Roever L. Ronfani L. Roshandel G. Rotimi K. Rout H.S. Roy B. Roy N. Roy P. Rubagotti E. S N C. Saad A.M.A. Saber-Ayad M.M. Sabour S. Sacco S. Sachdev P.S. Saddik B. Saddler A. Sadee B.A. Sadeghi E. Sadeghi M. Saeb M.R. Saeed U. Safi S.Z. Sagar R. Sagoe D. Saif Z. Sajid M.R. Sakshaug J.W. Salam N. Salami A.A. Salaroli L.B. Saleh M.A. Salem M.R. Salem M.Z.Y. Sallam M. Samadzadeh S. Samargandy S. Samodra Y.L. Samy A.M. Sanabria J. Sanna F. Santos I.S. Santric-Milicevic M.M. Sarasmita M.A. Sarikhani Y. Sarmiento-Suárez R. Sarode G.S. Sarode S.C. Sarveazad A. Sathian B. Sathyanarayan A. Satpathy M. Sawhney M. Scarmeas N. Schaarschmidt B.M. Schmidt M.I. Schneider I.J.C. Schumacher A.E. Schwebel D.C. Schwendicke F. Sedighi M. Senapati S. Senthilkumaran S. Sepanlou S.G. Sethi Y. Setoguchi S. Seylani A. Shadid J. Shafie M. Shah H. Shah N.S. Shah P.A. Shahbandi A. Shahid S. Shahid W. Shahwan M.J. Shaikh M.A. Shakeri A. Shalash A.S. Sham S. Shamim M.A. Shamshirgaran M.A. Shamsi M.A. Shanawaz M. Shankar A. Shannawaz M. Sharath M. Sharifan A. Sharifi-Rad J. Sharma M. Sharma R. Sharma S. Sharma U. Sharma V. Shastry R.P. Shavandi A. Shayan A.M. Shayan M. Shehabeldine A.M.E. Shetty P.H. Shibuya K. Shifa J.E. Shiferaw D. Shiferaw W.S. Shigematsu M. Shiri R. Shitaye N.A. Shittu A. Shivakumar K.M. Shivarov V. Shokati Eshkiki Z. Shool S. Shrestha S. Shuval K. Sibhat M.M. Siddig E.E. Sigfusdottir I.D. Silva D.A.S. Silva J.P. Silva L.M.L.R. Silva S. Simpson C.R. Singal A. Singh A. Singh B.B. Singh H. Singh J.A. Singh M. Singh P. Skou S.T. Sleet D.A. Slepak E.L.N. Solanki R. Soliman S.S.M. Song S. Song Y. Sorensen R.J.D. Soriano J.B. Soyiri I.N. Spartalis M. Sreeramareddy C.T. Stark B.A. Starodubova A.V. Stein C. Stein D.J. Steiner C. Steiner T.J. Steinmetz J.D. Steiropoulos P. Stockfelt L. Stokes M.A. Subedi N.S. Subramaniyan V. Suemoto C.K. Suleman M. Suliankatchi Abdulkader R. Sultana A. Sundström J. Swain C.K. Szarpak L. Tabaee Damavandi P. Tabarés-Seisdedos R. Tabatabaei Malazy O. Tabatabaeizadeh S-A. Tabatabai S. Tabche C. Tabish M. Tadakamadla S.K. Taheri Abkenar Y. Taheri Soodejani M. Taherkhani A. Taiba J. Talaat I.M. Talukder A. Tampa M. Tamuzi J.L. Tan K-K. Tandukar S. Tang H. Tavakoli Oliaee R. Tavangar S.M. Teimoori M. Temsah M-H. Teramoto M. Thangaraju P. Thankappan K.R. Thapar R. Thayakaran R. Thirunavukkarasu S. Thomas N. Thomas N.K. Thum C.C.C. Tichopad A. Ticoalu J.H.V. Tillawi T. Tiruye T.Y. Tobe-Gai R. Tonelli M. Topor-Madry R. Torre A.E. Touvier M. Tovani-Palone M.R. Tran J.T. Tran M.T.N. Tran N.M. Tran N-H. Trico D. Tromans S.J. Truyen T.T.T.T. Tsatsakis A. Tsegay G.M. Tsermpini E.E. Tumurkhuu M. Tyrovolas S. Udoh A. Umair M. Umakanthan S. Umar T.P. Undurraga E.A. Unim B. Unnikrishnan B. Unsworth C.A. Upadhyay E. Urso D. Usman J.S. Vahabi S.M. Vaithinathan A.G. Van den Eynde J. Varga O. Varma R.P. Vart P. Vasankari T.J. Vasic M. Vaziri S. Vellingiri B. Venketasubramanian N. Veroux M. Verras G-I. Vervoort D. Villafañe J.H. Violante F.S. Vlassov V. Vollset S.E. Volovat S.R. Vongpradith A. Waheed Y. Wang C. Wang F. Wang N. Wang S. Wang Y. Wang Y-P. Ward P. Wassie E.G. Weaver M.R. Weerakoon K.G. Weintraub R.G. Weiss D.J. Weldemariam A.H. Wells K.M. Wen Y.F. Whisnant J.L. Whiteford H.A. Wiangkham T. Wickramasinghe D.P. Wickramasinghe N.D. Wilandika A. Wilkerson C. Willeit P. Wimo A. Woldegebreal D.H. Wolf A.W. Wong Y.J. Woolf A.D. Wu C. Wu F. Wu X. Wu Z. Wulf Hanson S. Xia Y. Xiao H. Xu X. Xu Y.Y. Yadav L. Yadollahpour A. Yaghoubi S. Yamagishi K. Yang L. Yano Y. Yao Y. Yaribeygi H. Yazdanpanah M.H. Ye P. Yehualashet S.S. Yesuf S.A. Yezli S. Yiğit A. Yiğit V. Yigzaw Z.A. Yismaw Y. Yon D.K. Yonemoto N. Younis M.Z. Yu C. Yu Y. Yusuf H. Zahid M.H. Zakham F. Zaki L. Zaki N. Zaman B.A. Zamora N. Zand R. Zandieh G.G.Z. Zar H.J. Zarrintan A. Zastrozhin M.S. Zhang H. Zhang N. Zhang Y. Zhao H. Zhong C. Zhong P. Zhou J. Zhu Z. Ziafati M. Zielińska M. Zimsen S.R.M. Zoladl M. Zumla A. Zyoud S.H. Vos T. Murray C.J.L. GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024 403 10440 2133 2161 10.1016/S0140‑6736(24)00757‑8 38642570
    [Google Scholar]
  2. Hansen T.W. Jeppesen J. Rasmussen S. Ibsen H. Torp-Pedersen C. Ambulatory blood pressure and mortality: A population-based study. Hypertension 2005 45 4 499 504 10.1161/01.HYP.0000160402.39597.3b 15753229
    [Google Scholar]
  3. Oparil S. Acelajado M.C. Bakris G.L. Berlowitz D.R. Cífková R. Dominiczak A.F. Grassi G. Jordan J. Poulter N.R. Rodgers A. Whelton P.K. Hypertension. Nat. Rev. Dis. Primers 2018 4 1 18014 10.1038/nrdp.2018.14 29565029
    [Google Scholar]
  4. Carey R.M. Moran A.E. Whelton P.K. Treatment of hypertension. JAMA 2022 328 18 1849 1861 10.1001/jama.2022.19590 36346411
    [Google Scholar]
  5. Mancia G. Kreutz R. Brunström M. Burnier M. Grassi G. Januszewicz A. Muiesan M.L. Tsioufis K. Agabiti-Rosei E. Algharably E.A.E. Azizi M. Benetos A. Borghi C. Hitij J.B. Cifkova R. Coca A. Cornelissen V. Cruickshank J.K. Cunha P.G. Danser A.H.J. Pinho R.M. Delles C. Dominiczak A.F. Dorobantu M. Doumas M. Fernández-Alfonso M.S. Halimi J.M. Járai Z. Jelaković B. Jordan J. Kuznetsova T. Laurent S. Lovic D. Lurbe E. Mahfoud F. Manolis A. Miglinas M. Narkiewicz K. Niiranen T. Palatini P. Parati G. Pathak A. Persu A. Polonia J. Redon J. Sarafidis P. Schmieder R. Spronck B. Stabouli S. Stergiou G. Taddei S. Thomopoulos C. Tomaszewski M. Van de Borne P. Wanner C. Weber T. Williams B. Zhang Z.Y. Kjeldsen S.E. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J. Hypertens. 2023 41 12 1874 2071 10.1097/HJH.0000000000003480 37345492
    [Google Scholar]
  6. Toto R.D. Microalbuminuria: Definition, detection, and clinical significance. J. Clin. Hypertens. (Greenwich) 2004 6 s11 Suppl. 3 2 7 10.1111/j.1524‑6175.2004.4064.x 15538104
    [Google Scholar]
  7. Shin J.I. Chang A.R. Grams M.E. Coresh J. Ballew S.H. Surapaneni A. Matsushita K. Bilo H.J.G. Carrero J.J. Chodick G. Daratha K.B. Jassal S.K. Nadkarni G.N. Nelson R.G. Nowak C. Stempniewicz N. Sumida K. Traynor J.P. Woodward M. Sang Y. Gansevoort R.T. Chalmers J. Tuttle K. Alicic R. McPherson S. Jones C. Singh G. Green J. Kirchner H.L. Shalev V. Bottinger E.P. Loos R.J.F. Ellis S.B. Cuddeback J. Ciemins E. Carbonara E. Dunning S. Knowler W.C. Looker H.C. Kieneker L.M. Bakker S.J.L. Hillege H.L. van der Harst P. Jassal S.K. Bergstrom J. Ix J. Kovesdy C.P. Potukuchi P. Trevisan M. Elinder C.G. Wettermark B. Ärnlöv J. Mark P.B. Thomson P.C. Geddes C.C. Landman G.W.D. van Hateren K.J.J. Kleefstra N. Gutierrez O. Konta T. Levey A.S. Polkinghorne K. Schäffner E. Chen J. Surapeneni A. CKD Prognosis Consortium Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium. Hypertension 2021 78 4 1042 1052 10.1161/HYPERTENSIONAHA.121.17323 34365812
    [Google Scholar]
  8. McEvoy J.W. McCarthy C.P. Bruno R.M. Brouwers S. Canavan M.D. Ceconi C. Christodorescu R.M. Daskalopoulou S.S. Ferro C.J. Gerdts E. Hanssen H. Harris J. Lauder L. McManus R.J. Molloy G.J. Rahimi K. Regitz-Zagrosek V. Rossi G.P. Sandset E.C. Scheenaerts B. Staessen J.A. Uchmanowicz I. Volterrani M. Touyz R.M. Abreu A. Olsen M.H. Ambrosetti M. Androulakis E. Bang L.E. Bech J.N. Borger M.A. Boutouyrie P. Bronze L. Buccheri S. Dalmau R. De Pablo Zarzosa M.C. Delles C. Fiuza M.M. Gabulova R. Haugen B.O. Heiss C. Ibanez B. James S. Kapil V. Kayikçioglu M. Køber L. Koskinas K.C. Locati E.T. MacDonald S. Mihailidou A.S. Mihaylova B. Mindham R. Mortensen M.B. Nardai S. Neubeck L. Nielsen J.C. Nilsson P.M. Pasquet A.A. Pedro M.M. Prescott E. Rakisheva A. Rietzschel E. Rocca B. Rossello X. Schmid J-P. Shantsila E. Sudano I. Timóteo A.T. Tsivgoulis G. Ungar A. Vaartjes I. Visseren F. Voeller H. Vrints C. Witkowski A. Zennaro M-C. Zeppenfeld K. Shuka N. Laredj N. Pavo N. Mirzoyev U. van de Borne P. Sokolović Š. Postadzhiyan A. Samardzic J. Agathangelou P. Widimsky J. Olsen M.H. El-Kilany W.M. Pauklin P. Laukkanen J.A. Boulestreau R. Tsinamdzgvrishvili B. Kintscher U. Marketou M. Páll D. Hrafnkelsdóttir Þ.J. Dolan E. Wolak T. Bilo G. Tundybayeva M.K. Mirrakhimov E. Trusinskis K. Kiwan G. Msalem O. Badarienė J. Banu C-A. Balbi M.M. Caraus A. Boskovic A. Mouine N. Vromen T. Bosevski M. Midtbø H.B. Doroszko A. Dores H. Badila E. Bini R. Simić D.V. Fras Z. Mazón P. Spaak J. Burkard T. Barakat E. Abdessalem S. Gunes Y. Sirenko Y.M. Brady A.J.B. Khamidullaeva G.A. ESC Scientific Document Group 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 2024 45 38 3912 4018 10.1093/eurheartj/ehae178 39210715
    [Google Scholar]
  9. Mancia G. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 41 12 1874 2071 10.1097/HJH.0000000000003480
    [Google Scholar]
  10. Dimitriadis K. Schmieder R.E. Iliakis P. Nickel L. Tsioufis K. Weil J. Long-term efficacy and safety of renal denervation: An update from registries and randomised trials. Blood Press. 2023 32 1 2266664 10.1080/08037051.2023.2266664 37804153
    [Google Scholar]
  11. Tsioufis C. Dimitriadis K. Kasiakogias A. Kalos T. Liatakis I. Koutra E. Nikolopoulou L. Kordalis A. Ella R.O. Lau E.O.Y. Grassi G. Papademetriou V. Tousoulis D. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. J. Hypertens. 2017 35 5 1100 1108 10.1097/HJH.0000000000001262 28106665
    [Google Scholar]
  12. Nawar K. Mohammad A. Johns E.J. Abdulla M.H. Renal denervation for atrial fibrillation: A comprehensive updated systematic review and meta-analysis. J. Hum. Hypertens. 2022 36 10 887 897 10.1038/s41371‑022‑00658‑0 35094013
    [Google Scholar]
  13. Dimitriadis K. Iliakis P. Pyrpyris N. Tatakis F. Fragkoulis C. Mantziaris V. Plaitis A. Beneki E. Tsioufis P. Hering D. Kollias A. Konstantinidis D. Tsioufis K. Renal denervation in heart failure treatment: Data for a self-fulfilling prophecy. J. Clin. Med. 2024 13 22 6656 10.3390/jcm13226656 39597800
    [Google Scholar]
  14. Migliaro S. Petrolini A. Mariani S. Tomai F. Impact of renal denervation on patients with coronary microvascular dysfunction: Study rationale and design. J. Cardiovasc. Med. (Hagerstown) 2024 25 5 379 385 10.2459/JCM.0000000000001609 38477865
    [Google Scholar]
  15. Desai A.S. Webb D.J. Taubel J. Casey S. Cheng Y. Robbie G.J. Foster D. Huang S.A. Rhyee S. Sweetser M.T. Bakris G.L. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 2023 389 3 228 238 10.1056/NEJMoa2208391 37467498
    [Google Scholar]
  16. Gburek J. Konopska B. Gołąb K. Renal handling of albumin—from early findings to current concepts. Int. J. Mol. Sci. 2021 22 11 5809 10.3390/ijms22115809 34071680
    [Google Scholar]
  17. Gekle M. Renal tubule albumin transport. Annu. Rev. Physiol. 2005 67 1 573 594 10.1146/annurev.physiol.67.031103.154845 15709971
    [Google Scholar]
  18. Singh A. Satchell S.C. Microalbuminuria: Causes and implications. Pediatr. Nephrol. 2011 26 11 1957 1965 10.1007/s00467‑011‑1777‑1 21301888
    [Google Scholar]
  19. Ruilope L.M. Alcázar J.M. Rodicio J.L. Renal consequences of arterial hypertension. J. Hypertens. Suppl. 1992 10 7 S85 S90 1291661
    [Google Scholar]
  20. Cottone S. Cerasola G. Microalbuminuria fractional clearance and early renal permselectivity changes in essential hypertension. Am. J. Nephrol. 1992 12 5 326 329 10.1159/000168467 1489001
    [Google Scholar]
  21. Rodicio J.L. Campo C. Ruilope L.M. Microalbuminuria in essential hypertension. Kidney Int. 1998 54 S51 S54 10.1046/j.1523‑1755.1998.06813.x 9839284
    [Google Scholar]
  22. Tsioufis C. Dimitriadis K. Stefanadis C. Kallikazaros I. The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: Focus on microalbuminuria. Hellenic J. Cardiol. 2006 47 6 361 365 17243508
    [Google Scholar]
  23. Tsioufis C. Dimitriadis K. Taxiarchou E. Vasiliadou C. Chartzoulakis G. Tousoulis D. Manolis A. Stefanadis C. Kallikazaros I. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am. J. Hypertens. 2006 19 5 462 466 10.1016/j.amjhyper.2005.07.026 16647614
    [Google Scholar]
  24. Tsioufis C. Dimitriadis K. Andrikou E. Thomopoulos C. Tsiachris D. Stefanadi E. Mihas C. Miliou A. Papademetriou V. Stefanadis C. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: A cross-sectional study. Am. J. Kidney Dis. 2010 55 6 1050 1059 10.1053/j.ajkd.2009.11.024 20189274
    [Google Scholar]
  25. Ferrario C.M. Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am. J. Cardiol. 2006 98 1 121 128 10.1016/j.amjcard.2006.01.059 16784934
    [Google Scholar]
  26. Chen FQ. Levels of inflammatory cytokines in type 2 diabetes patients with different urinary albumin excretion rates and their correlation with clinical variables. J Diabetes Res. 2013 2013 138969 10.1155/2013/138969
    [Google Scholar]
  27. Wen Y. Crowley S.D. Renal effects of cytokines in hypertension. Curr. Opin. Nephrol. Hypertens. 2018 27 2 70 76 10.1097/MNH.0000000000000385 29140820
    [Google Scholar]
  28. Upadhyay A. Larson M.G. Guo C.Y. Vasan R.S. Lipinska I. O’Donnell C.J. Kathiresan S. Meigs J.B. Keaney J.F. Jr Rong J. Benjamin E.J. Fox C.S. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol. Dial. Transplant. 2011 26 3 920 926 10.1093/ndt/gfq471 20682604
    [Google Scholar]
  29. Garg J.P. Bakris G.L. Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc. Med. 2002 7 1 35 43 10.1191/1358863x02vm412ra 12083733
    [Google Scholar]
  30. Gallo G. Volpe M. Savoia C. Endothelial dysfunction in hypertension: Current concepts and clinical implications. Front. Med. (Lausanne) 2022 8 798958 10.3389/fmed.2021.798958 35127755
    [Google Scholar]
  31. Tsioufis C. Dimitriadis K. Antoniadis D. Stefanadis C. Kallikazaros I. Inter-Relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am. J. Hypertens. 2004 17 5 470 476 10.1016/j.amjhyper.2004.02.008 15110909
    [Google Scholar]
  32. Ochodnicky P. Henning R.H. van Dokkum R.P.E. de Zeeuw D. Microalbuminuria and endothelial dysfunction: Emerging targets for primary prevention of end-organ damage. J. Cardiovasc. Pharmacol. 2006 47 Suppl. 2 S151 S162 10.1097/00005344‑200606001‑00009 16794452
    [Google Scholar]
  33. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in Type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986 29 5 282 286 10.1007/BF00452063 3522326
    [Google Scholar]
  34. Nannipieri M. Rlzzo L. Rapuano A. Pilo A. Penno G. Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care 1995 18 1 1 9 10.2337/diacare.18.1.1 7698029
    [Google Scholar]
  35. Nannipieri M. Penno G. Rizzo L. Pucci L. Bandinelli S. Mattei P. Taddei S. Salvetti A. Navalesi R. Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension. Diabetes Care 1997 20 6 1019 1026 10.2337/diacare.20.6.1019 9167118
    [Google Scholar]
  36. Pedrinelli R. Penno G. Dell’Omo G. Bandinelli S. Giorgi D. Di Bello V. Navalesi R. Mariani M. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension 1999 34 3 491 495 10.1161/01.HYP.34.3.491 10489399
    [Google Scholar]
  37. Pedrinelli R. Giampietro O. Carmassi F. Melillo E. Dell’Omo G. Catapano G. Matteucci E. Talarico L. Morale M. De Negri F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994 344 8914 14 18 10.1016/S0140‑6736(94)91047‑2 7912295
    [Google Scholar]
  38. Blann A.D. McCollum C.N. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur. J. Vasc. Surg. 1994 8 1 10 15 10.1016/S0950‑821X(05)80112‑4 8307205
    [Google Scholar]
  39. Kario K. Matsuo T. Kobayashi H. Matsuo M. Sakata T. Miyata T. Shimada K. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. 1996 16 3 455 461 10.1161/01.ATV.16.3.455 8630673
    [Google Scholar]
  40. Cottone S. Vadalà A. Mangano M.T. Riccobene R. Vella M.C. Neri A.L. Mulé G. Piazza G. Amato F. Zagarrigo C. Cerasola G. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am. J. Hypertens. 2000 13 2 172 176 10.1016/S0895‑7061(99)00169‑7 10701817
    [Google Scholar]
  41. Cottone S. Mulè G. Nardi E. Lorito M.C. Guarneri M. Arsena R. Briolotta C. Vadalà A. Cerasola G. Microalbuminuria and early endothelial activation in essential hypertension. J. Hum. Hypertens. 2007 21 2 167 172 10.1038/sj.jhh.1002109 17051235
    [Google Scholar]
  42. Yu Y. Suo L. Yu H. Wang C. Tang H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res. Clin. Pract. 2004 65 2 95 104 10.1016/j.diabres.2004.01.006 15223221
    [Google Scholar]
  43. Agewall S. Lindstedt G. Fagerberg B. Independent relationship between microalbuminuria and plasminogen activator inhibitor-1 activity (PAI-1) activity in clinically healthy 58-year-old men. Atherosclerosis 2001 157 1 197 202 10.1016/S0021‑9150(00)00706‑1 11427221
    [Google Scholar]
  44. Zenere B.M. Arcaro G. Saggiani F. Rossi L. Muggeo M. Lechi A. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care 1995 18 7 975 982 10.2337/diacare.18.7.975 7555559
    [Google Scholar]
  45. Yokoyama H. Sone H. Saito K. Yamada D. Honjo J. Haneda M. Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes - interrelations with arterial thickness and stiffness. J. Atheroscler. Thromb. 2011 18 9 744 752 10.5551/jat.7526 21597231
    [Google Scholar]
  46. Ito H. Nakashima M. Meguro K. Furukawa H. Yamashita H. Takaki A. Yukawa C. Omoto T. Shinozaki M. Nishio S. Abe M. Antoku S. Mifune M. Togane M. Flow mediated dilatation is reduced with the progressive stages of glomerular filtration rate and albuminuria in type 2 diabetic patients without coronary heart disease. J. Diabetes Res. 2015 2015 1 9 10.1155/2015/728127 26064988
    [Google Scholar]
  47. Stehouwer C.D.A. Henry R.M.A. Dekker J.M. Nijpels G. Heine R.J. Bouter L.M. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study. Kidney Int. 2004 66 92 S42 S44 10.1111/j.1523‑1755.2004.09211.x 15485416
    [Google Scholar]
  48. Clausen P. Jensen J.S. Jensen G. Borch-Johnsen K. Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001 103 14 1869 1874 10.1161/01.CIR.103.14.1869 11294805
    [Google Scholar]
  49. Diercks G.F.H. Stroes E.S.G. Boven A.J. Roon A.M. Hillege H.L. Jong P.E. Smit A.J. Gans R.O.B. Crijns H.J.G.M. Rabelink T.J. Gilst W.H. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis 2002 163 1 121 126 10.1016/S0021‑9150(01)00748‑1 12048129
    [Google Scholar]
  50. Yun L. Xu R. Zhang L. Li G. Huang S. Yao Y. Li J. The role of microalbuminuria in arterial endothelial dysfunction in hypertensive patients with carotid plaques. Int. Heart J. 2014 55 2 153 159 10.1536/ihj.13‑232 24632956
    [Google Scholar]
  51. Taddei S. Virdis A. Mattei P. Ghiadoni L. Sudano I. Arrighi P. Salvetti A. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. J. Hypertens. 1995 13 9 1003 1008 10.1097/00004872‑199509000‑00010 8586817
    [Google Scholar]
  52. Bezante G.P. Viazzi F. Leoncini G. Ratto E. Conti N. Balbi M. Agosti S. Deferrari L. Deferrari G. Pontremoli R. Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage. Am. J. Hypertens. 2009 22 2 191 196 10.1038/ajh.2008.351 19151691
    [Google Scholar]
  53. Jadoul M. Aoun M. Masimango Imani M. The major global burden of chronic kidney disease. Lancet Glob. Health 2024 12 3 e342 e343 10.1016/S2214‑109X(24)00050‑0 38365398
    [Google Scholar]
  54. Rangaswami J. Bhalla V. Blair J.E.A. Chang T.I. Costa S. Lentine K.L. Lerma E.V. Mezue K. Molitch M. Mullens W. Ronco C. Tang W.H.W. McCullough P.A. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation 2019 139 16 e840 e878 10.1161/CIR.0000000000000664 30852913
    [Google Scholar]
  55. Jankowski J. Floege J. Fliser D. Böhm M. Marx N. Cardiovascular disease in chronic kidney disease. Circulation 2021 143 11 1157 1172 10.1161/CIRCULATIONAHA.120.050686 33720773
    [Google Scholar]
  56. Stevens P.E. Ahmed S.B. Carrero J.J. Foster B. Francis A. Hall R.K. Herrington W.G. Hill G. Inker L.A. Kazancıoğlu R. Lamb E. Lin P. Madero M. McIntyre N. Morrow K. Roberts G. Sabanayagam D. Schaeffner E. Shlipak M. Shroff R. Tangri N. Thanachayanont T. Ulasi I. Wong G. Yang C-W. Zhang L. Levin A. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 105 4 S117 S314 10.1016/j.kint.2023.10.018 38490803
    [Google Scholar]
  57. Matsushita K. van der Velde M. Astor B.C. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: A collaborative meta-analysis of general population cohorts. Lancet 2010 375 9731 2073 10.1016/S0140‑6736(10)60674‑5 20483451
    [Google Scholar]
  58. Hemmelgarn B.R. Manns B.J. Lloyd A. James M.T. Klarenbach S. Quinn R.R. Wiebe N. Tonelli M. Alberta Kidney Disease Network Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010 303 5 423 429 10.1001/jama.2010.39 20124537
    [Google Scholar]
  59. Matsushita K. van der Velde M. Astor B.C. Woodward M. Levey A.S. de Jong P.E. Coresh J. Gansevoort R.T. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010 375 9731 2073 2081 10.1016/S0140‑6736(10)60674‑5 20483451
    [Google Scholar]
  60. Koye D.N. Magliano D.J. Reid C.M. Jepson C. Feldman H.I. Herman W.H. Shaw J.E. Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: The CRIC (Chronic Renal Insufficiency Cohort) study. Am. J. Kidney Dis. 2018 72 5 653 661 10.1053/j.ajkd.2018.02.364 29784612
    [Google Scholar]
  61. Babazono T. Hanai K. Yokoyama Y. Uchiyama K. Association between 1-year changes in urinary albumin-to-creatinine ratio and kidney disease progression in Japanese individuals with diabetes: A historical cohort study. Clin. Exp. Nephrol. 2023 27 12 1001 1009 10.1007/s10157‑023‑02380‑8 37606804
    [Google Scholar]
  62. Verma A. Schmidt I.M. Claudel S. Palsson R. Waikar S.S. Srivastava A. Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria. Ann. Intern. Med. 2024 177 4 467 475 10.7326/M23‑2814 38560911
    [Google Scholar]
  63. Tangri N. Stevens L.A. Griffith J. Tighiouart H. Djurdjev O. Naimark D. Levin A. Levey A.S. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011 305 15 1553 1559 10.1001/jama.2011.451 21482743
    [Google Scholar]
  64. Hallan S.I. Ritz E. Lydersen S. Romundstad S. Kvenild K. Orth S.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 2009 20 5 1069 1077 10.1681/ASN.2008070730 19357254
    [Google Scholar]
  65. Tonelli M. Muntner P. Lloyd A. Manns B.J. James M.T. Klarenbach S. Quinn R.R. Wiebe N. Hemmelgarn B.R. Alberta Kidney Disease Network Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: A cohort study. Ann. Intern. Med. 2011 154 1 12 21 10.7326/0003‑4819‑154‑1‑201101040‑00003 21200034
    [Google Scholar]
  66. Hsu C.Y. Ordoñez J.D. Chertow G.M. Fan D. McCulloch C.E. Go A.S. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 74 1 101 107 10.1038/ki.2008.107 18385668
    [Google Scholar]
  67. Grams M.E. Astor B.C. Bash L.D. Matsushita K. Wang Y. Coresh J. Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J. Am. Soc. Nephrol. 2010 21 10 1757 1764 10.1681/ASN.2010010128 20671214
    [Google Scholar]
  68. James M.T. Hemmelgarn B.R. Wiebe N. Pannu N. Manns B.J. Klarenbach S.W. Tonelli M. Alberta Kidney Disease Network Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: A cohort study. Lancet 2010 376 9758 2096 2103 10.1016/S0140‑6736(10)61271‑8 21094997
    [Google Scholar]
  69. James M.T. Grams M.E. Woodward M. Elley C.R. Green J.A. Wheeler D.C. de Jong P. Gansevoort R.T. Levey A.S. Warnock D.G. Sarnak M.J. Tonelli M. Hemmelgarn B.R. James M.T. Turin T.C. Coresh J. Matsushita K. Grams M. Sang Y. Shlipak M. Sarnak M.J. Katz R. Wheeler D.C. Emberson J. Landray M.J. Townend J.N. Green J. Kirchner H.L. Perkins R. Chang A.R. Romundstad S. Aasarød K. Øien C.M. Hallan S. Smith D.H. Thorp M.L. Johnson E.S. Chodick G. Herzel E. Katz R. Shalev V. Gansevoort R.T. Bakker S.J.L. Lambers Heerspink H.J. van der Harst P. Jee S.H. Kimm H. Mok Y. Tangri N. Naimark D. Ärnlöv J. Larsson A. Lannfelt L. Kovesdy C.P. Kalantar-Zadeh K. Coresh J. Grams M. Matsushita K. Gansevoort R.T. de Jong P.E. Iseki K. Levey A.S. Sarnak M.J. Stengel B. Warnock D. Woodward M. Ballew S.H. Coresh J. Grams M. Matsushita K. Sang Y. Woodward M. CKD Prognosis Consortium A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am. J. Kidney Dis. 2015 66 4 602 612 10.1053/j.ajkd.2015.02.338 25975964
    [Google Scholar]
  70. Hsu, C-Y.; Chinchilli, V.M.; Coca, S.; Devarajan, P.; Ghahramani, N.; Go, A.S.; Hsu, R.K.; Ikizler, T.A.; Kaufman, J.; Liu, K.D.; Parikh, C.R.; Reeves, W.B.; Wurfel, M.; Zappitelli, M.; Kimmel, P.L.; Siew, E.D. Post-acute kidney injury proteinuria and subsequent kidney disease progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study. JAMA Intern. Med. 2020 180 3 402 410 10.1001/jamainternmed.2019.6390
    [Google Scholar]
  71. Parving H.H. Mogensen C.E. Jensen H.Æ. Evrin P.E. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet 1974 303 7868 1190 1192 10.1016/S0140‑6736(74)91002‑2 4134681
    [Google Scholar]
  72. Bigazzi R. Bianchi S. Campese V.M. Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron J. 1992 61 1 94 97 10.1159/000186842 1528348
    [Google Scholar]
  73. Fici F. Bakir E.A. Beyaz S. Makel W. Robles N.R. PAIT-survey—Prevalence of albuminuria in patients with diabetes and hypertension in Turkey. Prim. Care Diabetes 2018 12 6 558 564 10.1016/j.pcd.2018.08.008 30327190
    [Google Scholar]
  74. Pedrinelli R. Dell’Omo G. Di Bello V. Pontremoli R. Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J. Hum. Hypertens. 2002 16 2 79 89 10.1038/sj.jhh.1001316 11850764
    [Google Scholar]
  75. Tsakiris A. Doumas M. Lagatouras D. Vyssoulis G. Karpanou E. Nearchou N. Kouremenou C. Skoufas P. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: The Three Areas Study in Greece (TAS-GR). Angiology 2006 57 3 313 320 10.1177/000331970605700307 16703191
    [Google Scholar]
  76. Agewall S. Fagerberg B. The Risk Factor Intervention Study Group Risk factors that predict development of microalbuminuria in treated hypertensive men. Angiology 1996 47 10 963 972 10.1177/000331979604701005 8873582
    [Google Scholar]
  77. Palatini P. Mormino P. Santonastaso M. Mos L. Dal Follo M. Zanata G. Pessina A.C. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998 31 1 57 63 10.1161/01.HYP.31.1.57 9449391
    [Google Scholar]
  78. Hata J. Fukuhara M. Sakata S. Arima H. Hirakawa Y. Yonemoto K. Mukai N. Kitazono T. Kiyohara Y. Ninomiya T. White-coat and masked hypertension are associated with albuminuria in a general population: The Hisayama Study. Hypertens. Res. 2017 40 11 937 943 10.1038/hr.2017.74 28878300
    [Google Scholar]
  79. Knight E.L. Kramer H.M. Curhan G.C. High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. 2003 41 3 588 595 10.1053/ajkd.2003.50120 12612982
    [Google Scholar]
  80. Jiang X. Srinivasan S.R. Radhakrishnamurthy B. Dalferes E.R. Jr Bao W. Berenson G.S. Microalbuminuria in young adults related to blood pressure in a biracial (black-white) population. The Bogalusa Heart Study. Am. J. Hypertens. 1994 7 9_Pt_1 794 800 10.1093/ajh/7.9.794 7811437
    [Google Scholar]
  81. de la Sierra A. Banegas J.R. Oliveras A. Gorostidi M. Segura J. de la Cruz J.J. Armario P. Ruilope L.M. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J. Hypertens. 2012 30 6 1211 1216 10.1097/HJH.0b013e328353634e 22525201
    [Google Scholar]
  82. Bianchi S. Bigazzi R. Baldari G. Sgherri G. Campese V.M. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am. J. Hypertens. 1994 7 1 23 29 10.1093/ajh/7.1.23 8136107
    [Google Scholar]
  83. Afsar B. Elsurer R. Urinary albumin excretion among nondipper hypertensive patients is closely related with the pattern of nondipping. J. Am. Soc. Hypertens. 2010 4 4 196 202 10.1016/j.jash.2010.06.004 20655503
    [Google Scholar]
  84. Oliveras A. Armario P. Martell-Clarós N. Ruilope L.M. de la Sierra A. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension 2011 57 3 556 560 10.1161/HYPERTENSIONAHA.110.165563 21220713
    [Google Scholar]
  85. Agrawal B. Berger A. Wolf K. Luft F.C. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J. Hypertens. 1996 14 2 223 228 10.1097/00004872‑199602000‑00011 8728300
    [Google Scholar]
  86. Yudkin J. Forrest R. Jackson C. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988 332 8610 530 533 10.1016/S0140‑6736(88)92657‑8 2900920
    [Google Scholar]
  87. Ljungman S. Wikstrand J. Hartford M. Berglund G. Urinary albumin excretion — A predictor of risk of cardiovascular disease A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am. J. Hypertens. 1996 9 8 770 778 10.1016/0895‑7061(96)00102‑1 8862223
    [Google Scholar]
  88. Agewall S. Wikstrand J. Ljungman S. Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am. J. Cardiol. 1997 80 2 164 169 10.1016/S0002‑9149(97)00312‑3 9230153
    [Google Scholar]
  89. Miettinen H. Haffner S.M. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996 27 11 2033 2039 10.1161/01.STR.27.11.2033 8898811
    [Google Scholar]
  90. Jager A. Kostense P.J. Ruhé H.G. Heine R.J. Nijpels G. Dekker J.M. Bouter L.M. Stehouwer C.D.A. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arterioscler. Thromb. Vasc. Biol. 1999 19 3 617 624 10.1161/01.ATV.19.3.617 10073965
    [Google Scholar]
  91. Hillege H.L. Fidler V. Diercks G.F.H. van Gilst W.H. de Zeeuw D. van Veldhuisen D.J. Gans R.O.B. Janssen W.M.T. Grobbee D.E. de Jong P.E. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 106 14 1777 1782 10.1161/01.CIR.0000031732.78052.81 12356629
    [Google Scholar]
  92. Gerstein H.C. Mann J.F. Yi Q. Zinman B. Dinneen S.F. Hoogwerf B. Hallé J.P. Young J. Rashkow A. Joyce C. Nawaz S. Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 286 4 421 426 10.1001/jama.286.4.421 11466120
    [Google Scholar]
  93. Jensen J.S. Feldt-Rasmussen B. Strandgaard S. Schroll M. Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000 35 4 898 903 10.1161/01.HYP.35.4.898 10775558
    [Google Scholar]
  94. Bigazzi R. Bianchi S. Baldari D. Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J. Hypertens. 1998 16 9 1325 1333 10.1097/00004872‑199816090‑00014 9746120
    [Google Scholar]
  95. Wachtell K. Ibsen H. Olsen M.H. Borch-Johnsen K. Lindholm L.H. Mogensen C.E. Dahlöf B. Devereux R.B. Beevers G. de Faire U. Fyhrquist F. Julius S. Kjeldsen S.E. Kristianson K. Lederballe-Pedersen O. Nieminen M.S. Okin P.M. Omvik P. Oparil S. Wedel H. Snapinn S.M. Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003 139 11 901 906 10.7326/0003‑4819‑139‑11‑200312020‑00008 14644892
    [Google Scholar]
  96. Gerdts E. Okin P.M. Omvik P. Wachtell K. Dahlöf B. Hildebrandt P. Nieminen M.S. Devereux R.B. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr. Metab. Cardiovasc. Dis. 2009 19 5 306 312 10.1016/j.numecd.2008.12.009 19303268
    [Google Scholar]
  97. Pascual J.M. Rodilla E. Costa J.A. Garcia-Escrich M. Gonzalez C. Redon J. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2014 64 6 1228 1234 10.1161/HYPERTENSIONAHA.114.04273 25245391
    [Google Scholar]
  98. Romundstad S. Holmen J. Hallan H. Kvenild K. Ellekjær H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: Does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway. Circulation 2003 108 22 2783 2789 10.1161/01.CIR.0000103667.27493.32 14623803
    [Google Scholar]
  99. Hong Z. Jiang Y. Liu P. Zhang L. Association of microalbuminuria and adverse outcomes in hypertensive patients: A meta-analysis. Int. Urol. Nephrol. 2021 53 11 2311 2319 10.1007/s11255‑021‑02795‑w 33674949
    [Google Scholar]
  100. Tsioufis C. Stefanadis C. Toutouza M. Kallikazaros I. Toutouzas K. Tousoulis D. Pitsavos C. Papademetriou V. Toutouzas P. Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. J. Hum. Hypertens. 2002 16 4 249 254 10.1038/sj.jhh.1001379 11967718
    [Google Scholar]
  101. Pontremoli R. Ravera M. Bezante G.P. Viazzi F. Nicolella C. Berruti V. Leoncini G. Sette M.D. Brunelli C. Tomolillo C. Deferrari G. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J. Hypertens. 1999 17 7 993 1000 10.1097/00004872‑199917070‑00016 10419073
    [Google Scholar]
  102. Lieb W. Mayer B. Stritzke J. Doering A. Hense H.W. Loewel H. Erdmann J. Schunkert H. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population. Nephrol. Dial. Transplant. 2006 21 10 2780 2787 10.1093/ndt/gfl364 16880179
    [Google Scholar]
  103. Pontremoli R. Sofia A. Ravera M. Nicolella C. Viazzi F. Tirotta A. Ruello N. Tomolillo C. Castello C. Grillo G. Sacchi G. Deferrari G. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997 30 5 1135 1143 10.1161/01.HYP.30.5.1135 9369267
    [Google Scholar]
  104. Dell’omo G. Giorgi D. Di Bello V. Mariani M. Pedrinelli R. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J. Intern. Med. 2003 254 1 76 84 10.1046/j.1365‑2796.2003.01155.x 12823644
    [Google Scholar]
  105. Tsioufis C.P. Lambrou S.G. Stefanadis C.I. Antoniadis D.I. Kallikazaros I.E. Pitsavos C.E. Toutouzas P.K. Microalbuminuria is associated with abnormal thoracic aortic mechanics in essential hypertension. Am. J. Cardiol. 2000 86 7 797 801, A9 10.1016/S0002‑9149(00)01087‑0 11018207
    [Google Scholar]
  106. Losito A. Fortunati F. Zampi I. Del Favero A. Impaired renal functional reserve and albuminuria in essential hypertension. BMJ 1988 296 6636 1562 1564 10.1136/bmj.296.6636.1562 3135009
    [Google Scholar]
  107. Mulè G. Cottone S. Vadalà A. Volpe V. Mezzatesta G. Mongiovì R. Piazza G. Nardi E. Andronico G. Cerasola G. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J. Intern. Med. 2004 256 1 22 29 10.1111/j.1365‑2796.2004.01338.x 15189362
    [Google Scholar]
  108. Mulè G. Cottone S. Cusimano P. Riccobene R. Palermo A. Geraci C. Nardi E. Bellavia T. Foraci A.C. Cerasola G. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension. Am. J. Hypertens. 2009 22 10 1041 1047 10.1038/ajh.2009.132 19629049
    [Google Scholar]
  109. Sarafidis P. Use of ACEi/ARBs, SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD. Clin. Kidney J. 2024 17 2 sfae014 10.1093/ckj/sfae014
    [Google Scholar]
  110. Gerstein H.C. Yusuf S. Mann J.F.E. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 9200 253 259 10.1016/S0140‑6736(99)12323‑7 10675071
    [Google Scholar]
  111. Asselbergs F.W. Diercks G.F.H. Hillege H.L. van Boven A.J. Janssen W.M.T. Voors A.A. de Zeeuw D. de Jong P.E. van Veldhuisen D.J. van Gilst W.H. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004 110 18 2809 2816 10.1161/01.CIR.0000146378.65439.7A 15492322
    [Google Scholar]
  112. Ruggenenti P. Fassi A. Ilieva A.P. Bruno S. Iliev I.P. Brusegan V. Rubis N. Gherardi G. Arnoldi F. Ganeva M. Ene-Iordache B. Gaspari F. Perna A. Bossi A. Trevisan R. Dodesini A.R. Remuzzi G. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004 351 19 1941 1951 10.1056/NEJMoa042167 15516697
    [Google Scholar]
  113. Ruggenenti P. Fassi A. Ilieva A.P. Iliev I.P. Chiurchiu C. Rubis N. Gherardi G. Ene-Iordache B. Gaspari F. Perna A. Cravedi P. Bossi A. Trevisan R. Motterlini N. Remuzzi G. BENEDICT-B Study Investigators Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J. Hypertens. 2011 29 2 207 216 10.1097/HJH.0b013e32834069bd 21243736
    [Google Scholar]
  114. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 370 9590 829 40 10.1016/S0140‑6736(07)61303‑8
    [Google Scholar]
  115. Parving H.H. Lehnert H. Bröchner-Mortensen J. Gomis R. Andersen S. Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001 345 12 870 878 10.1056/NEJMoa011489 11565519
    [Google Scholar]
  116. Viberti G. Wheeldon N.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 106 6 672 678 10.1161/01.CIR.0000024416.33113.0A 12163426
    [Google Scholar]
  117. Makino H. Haneda M. Babazono T. Moriya T. Ito S. Iwamoto Y. Kawamori R. Takeuchi M. Katayama S. INNOVATION Study Group Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 30 6 1577 1578 10.2337/dc06‑1998 17389334
    [Google Scholar]
  118. Menne J. Izzo J.L. Jr Ito S. Januszewicz A. Katayama S. Chatzykirkou C. Mimran A. Rabelink T.J. Ritz E. Ruilope L.M. Rump L.C. Viberti G. Haller H. ROADMAP investigators Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J. Hypertens. 2012 30 4 811 818 10.1097/HJH.0b013e328351856d 22418908
    [Google Scholar]
  119. Dahlöf B. Devereux R.B. Kjeldsen S.E. Julius S. Beevers G. de Faire U. Fyhrquist F. Ibsen H. Kristiansson K. Lederballe-Pedersen O. Lindholm L.H. Nieminen M.S. Omvik P. Oparil S. Wedel H. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 9311 995 1003 10.1016/S0140‑6736(02)08089‑3 11937178
    [Google Scholar]
  120. Ibsen H. Wachtell K. Olsen M.H. Borch-Johnsen K. Lindholm L.H. Mogensen C.E. Dahlöf B. Devereux R.B. de Faire U. Fyhrquist F. Julius S. Kjeldsen S.E. Lederballe-Pedersen O. Nieminen M.S. Omvik P. Oparil S. Wan Y. LIFE substudy Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. 2004 22 9 1805 1811 10.1097/00004872‑200409000‑00026 15311110
    [Google Scholar]
  121. Natale P. Palmer S.C. Navaneethan S.D. Craig J.C. Strippoli G.F.M. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Libr. 2024 2024 5 CD006257 10.1002/14651858.CD006257.pub2 38682786
    [Google Scholar]
  122. Bakris G.L. Ruilope L. Locatelli F. Ptaszynska A. Pieske B. de Champlain J. Weber M.A. Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int. 2007 72 7 879 885 10.1038/sj.ki.5002455 17667984
    [Google Scholar]
  123. Mann J.F.E. Schmieder R.E. McQueen M. Dyal L. Schumacher H. Pogue J. Wang X. Maggioni A. Budaj A. Chaithiraphan S. Dickstein K. Keltai M. Metsärinne K. Oto A. Parkhomenko A. Piegas L.S. Svendsen T.L. Teo K.K. Yusuf S. ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372 9638 547 553 10.1016/S0140‑6736(08)61236‑2 18707986
    [Google Scholar]
  124. Ruggenenti P. Cortinovis M. Parvanova A. Trillini M. Iliev I.P. Bossi A.C. Belviso A. Aparicio M.C. Trevisan R. Rota S. Perna A. Peracchi T. Rubis N. Martinetti D. Prandini S. Gaspari F. Carrara F. De Cosmo S. Tonolo G. Mangili R. Remuzzi G. VARIETY Study Organization Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS Med. 2021 18 7 e1003691 10.1371/journal.pmed.1003691 34260595
    [Google Scholar]
  125. Currie G. Taylor A.H.M. Fujita T. Ohtsu H. Lindhardt M. Rossing P. Boesby L. Edwards N.C. Ferro C.J. Townend J.N. van den Meiracker A.H. Saklayen M.G. Oveisi S. Jardine A.G. Delles C. Preiss D.J. Mark P.B. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016 17 1 127 10.1186/s12882‑016‑0337‑0 27609359
    [Google Scholar]
  126. Nielsen S.E. Persson F. Frandsen E. Sugaya T. Hess G. Zdunek D. Shjoedt K.J. Parving H-H. Rossing P. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet. Med. 2012 29 8 e184 e190 10.1111/j.1464‑5491.2012.03585.x 22268920
    [Google Scholar]
  127. Ziaee A. Vaezi A.A. Oveisi S. Javadi A. Hashemipour S. Kazemifar A.M. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial. Caspian J. Intern. Med. 2013 4 2 648 653 24009953
    [Google Scholar]
  128. Chen Y. Liu P. Chen X. Li Y. Zhang F. Wang Y. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am. J. Med. Sci. 2018 355 5 418 424 10.1016/j.amjms.2018.01.017 29753370
    [Google Scholar]
  129. Ando K. Ohtsu H. Uchida S. Kaname S. Arakawa Y. Fujita T. EVALUATE Study Group Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 2 12 944 953 10.1016/S2213‑8587(14)70194‑9 25466242
    [Google Scholar]
  130. El Mokadem M. Abd El Hady Y. Aziz A. A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy. Cardiorenal Med. 2020 10 6 392 401 10.1159/000508670 32998143
    [Google Scholar]
  131. Agarwal R. Kolkhof P. Bakris G. Bauersachs J. Haller H. Wada T. Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 2021 42 2 152 161 10.1093/eurheartj/ehaa736 33099609
    [Google Scholar]
  132. Bakris G.L. Agarwal R. Anker S.D. Pitt B. Ruilope L.M. Rossing P. Kolkhof P. Nowack C. Schloemer P. Joseph A. Filippatos G. FIDELIO-DKD Investigators Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020 383 23 2219 2229 10.1056/NEJMoa2025845 33264825
    [Google Scholar]
  133. Pitt B. Filippatos G. Agarwal R. Anker S.D. Bakris G.L. Rossing P. Joseph A. Kolkhof P. Nowack C. Schloemer P. Ruilope L.M. FIGARO-DKD Investigators Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 2021 385 24 2252 2263 10.1056/NEJMoa2110956 34449181
    [Google Scholar]
  134. Skrabic, R.; Kumric, M.; Vrdoljak, J.; Rusic, D.; Skrabic, I.; Vilovic, M.; Martinovic, D.; Duplancic, V.; Kurir, T.T.; Bozic, J. SGLT2 inhibitors in chronic kidney disease: From mechanisms to clinical practice. Biomedicines 2022 10 10 2458 10.3390/biomedicines10102458
    [Google Scholar]
  135. Waijer S.W. Xie D. Inzucchi S.E. Zinman B. Koitka-Weber A. Mattheus M. von Eynatten M. Inker L.A. Wanner C. Heerspink H.J.L. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: A post hoc analysis of the empa-reg outcome trial. J. Am. Heart Assoc. 2020 9 18 e016976 10.1161/JAHA.120.016976 32893717
    [Google Scholar]
  136. Neal B. Perkovic V. Mahaffey K.W. de Zeeuw D. Fulcher G. Erondu N. Shaw W. Law G. Desai M. Matthews D.R. CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017 377 7 644 657 10.1056/NEJMoa1611925 28605608
    [Google Scholar]
  137. Neuen B.L. Ohkuma T. Neal B. Matthews D.R. de Zeeuw D. Mahaffey K.W. Fulcher G. Li Q. Jardine M. Oh R. Heerspink H.L. Perkovic V. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program. J. Am. Soc. Nephrol. 2019 30 11 2229 2242 10.1681/ASN.2019010064 31530577
    [Google Scholar]
  138. Wiviott S.D. Raz I. Bonaca M.P. Mosenzon O. Kato E.T. Cahn A. Silverman M.G. Zelniker T.A. Kuder J.F. Murphy S.A. Bhatt D.L. Leiter L.A. McGuire D.K. Wilding J.P.H. Ruff C.T. Gause-Nilsson I.A.M. Fredriksson M. Johansson P.A. Langkilde A.M. Sabatine M.S. DECLARE–TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019 380 4 347 357 10.1056/NEJMoa1812389 30415602
    [Google Scholar]
  139. Mosenzon O. Wiviott S.D. Heerspink H.J.L. Dwyer J.P. Cahn A. Goodrich E.L. Rozenberg A. Schechter M. Yanuv I. Murphy S.A. Zelniker T.A. Gause-Nilsson I.A.M. Langkilde A.M. Fredriksson M. Johansson P.A. Bhatt D.L. Leiter L.A. McGuire D.K. Wilding J.P.H. Sabatine M.S. Raz I. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care 2021 44 8 1805 1815 10.2337/dc21‑0076 34233928
    [Google Scholar]
  140. Perkovic V. Jardine M.J. Neal B. Bompoint S. Heerspink H.J.L. Charytan D.M. Edwards R. Agarwal R. Bakris G. Bull S. Cannon C.P. Capuano G. Chu P.L. de Zeeuw D. Greene T. Levin A. Pollock C. Wheeler D.C. Yavin Y. Zhang H. Zinman B. Meininger G. Brenner B.M. Mahaffey K.W. CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260
    [Google Scholar]
  141. Oshima M. Neuen B.L. Li J. Perkovic V. Charytan D.M. de Zeeuw D. Edwards R. Greene T. Levin A. Mahaffey K.W. De Nicola L. Pollock C. Rosenthal N. Wheeler D.C. Jardine M.J. Heerspink H.J.L. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial. J. Am. Soc. Nephrol. 2020 31 12 2925 2936 10.1681/ASN.2020050723 32998938
    [Google Scholar]
  142. Jongs N. Greene T. Chertow G.M. McMurray J.J.V. Langkilde A.M. Correa-Rotter R. Rossing P. Sjöström C.D. Stefansson B.V. Toto R.D. Wheeler D.C. Heerspink H.J.L. DAPA-CKD Trial Committees and Investigators Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 9 11 755 766 10.1016/S2213‑8587(21)00243‑6 34619106
    [Google Scholar]
  143. Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; Ng, S.Y.A.; Sammons, E.; Zhu, D.; Hill, M.; Stevens, W.; Wallendszus, K.; Brenner, S.; Cheung, A.K.; Liu, Z-H.; Li, J.; Hooi, L.S.; Liu, W.; Kadowaki, T.; Nangaku, M.; Levin, A.; Cherney, D.; Maggioni, A.P.; Pontremoli, R.; Deo, R.; Goto, S.; Rossello, X.; Tuttle, K.R.; Steubl, D.; Petrini, M.; Massey, D.; Eilbracht, J.; Brueckmann, M.; Landray, M.J.; Baigent, C.; Haynes, R. Empagliflozin in patients with cronic kdney dsease. N. Engl. J. Med. 2023 388 2 117 127 10.1056/NEJMoa2204233 36331190
    [Google Scholar]
  144. Tangri N. Rastogi A. Nekeman-Nan C. Hong L.S. Ozaki A. Franzén S. Sofue T. Dapagliflozin utilization in chronic kidney disease and its real-world effectiveness among patients with lower levels of albuminuria in the USA and Japan. Adv. Ther. 2024 41 3 1151 1167 10.1007/s12325‑023‑02773‑x 38240949
    [Google Scholar]
  145. Ferreira J.P. Zannad F. Butler J. Filippatos G. Pocock S.J. Brueckmann M. Steubl D. Schueler E. Anker S.D. Packer M. Association of empagliflozin treatment with albuminuria levels in patients with heart failure. JAMA Cardiol. 2022 7 11 1148 1159 10.1001/jamacardio.2022.2924 36129693
    [Google Scholar]
  146. Alicic R.Z. Cox E.J. Neumiller J.J. Tuttle K.R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2020 17 4 227 244 10.1038/s41581‑020‑00367‑2
    [Google Scholar]
  147. Yuan D. Sharma H. Krishnan A. Vangaveti V.N. Malabu U.H. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes. Metab. 2022 24 9 1869 1881 10.1111/dom.14776 35589615
    [Google Scholar]
  148. Tuttle K.R. Lakshmanan M.C. Rayner B. Busch R.S. Zimmermann A.G. Woodward D.B. Botros F.T. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018 6 8 605 617 10.1016/S2213‑8587(18)30104‑9 29910024
    [Google Scholar]
  149. Gerstein H.C. Colhoun H.M. Dagenais G.R. Diaz R. Lakshmanan M. Pais P. Probstfield J. Botros F.T. Riddle M.C. Rydén L. Xavier D. Atisso C.M. Dyal L. Hall S. Rao-Melacini P. Wong G. Avezum A. Basile J. Chung N. Conget I. Cushman W.C. Franek E. Hancu N. Hanefeld M. Holt S. Jansky P. Keltai M. Lanas F. Leiter L.A. Lopez-Jaramillo P. Cardona Munoz E.G. Pirags V. Pogosova N. Raubenheimer P.J. Shaw J.E. Sheu W.H.H. Temelkova-Kurktschiev T. Abella M. Alebuena A. Almagro S. Amoroso E. Anadon P. Andreu E. Aristimuño G. Arzadun M. Barbieri M. Barcudi R. Bartolacci I. Bolobanich G. Bordonava A. Bustamante Labarta M. Bustos B. Caccavo A. Camino A. Cantero M. Carignano M. Cartasegna L. Cipullo M. Commendatore V. Conosciuto V. Costamagna O. Crespo C. Cuello J. Cuneo C. Cusimano S. Dean S. Dituro C. Dominguez A. Farah M. Fernandez A. Fernandez F. Ferrari A. Flammia P. Fuentealba J. Gallardo K.B. Garcia C. Garcia Duran R. Garrido M. Gavicola R. Gerbaudo C. Gilli G. Giotto A.P. Godoy Bolzán P. Gomez Vilamajo O. Guerlloy F. Guridi C. Gutierrez Garrido N. Hasbani E. Hermida S. Hominal M. Hrabar A. Ingaramo A. Izzicupo A. Krynski M. Lagrutta M. Lanchiotti P. Langhe M. Leonard V. Llanos J. Lopez Santi R. Lowenstein J. Luquez C. Mackinnon I. Mana M. Manzur S. Marino J. Martella C. Martinez R. Matias R. Matkovich J. Meritano M. Montaña O. Mulazzi M. Ochoa J. Paterlini G. Pelagagge M. Peralta Lopez M.E. Prado A. Pruyas L. Racca M. Ricotti C. Rodriguez C. Romero Vidomlansky M. Ronderos R. Sadowski A.L. Sala J. Sánchez A. Santoro A. Schiavi L. Sein M. Sernia V. Serra L. Sicer M. Smith T. Soso L. Sposetti G. Steinacher A. Stival J. Tedesco J. Tonin H. Tortolo M. Ulla M. Vallejos J. Vico M. Virgillito L. Visco V. Vogel D. Waisman F. Zaidman C. Zucchiatti N. Badshah I. Cohen N. Colman P. Colquhoun D. Davis T. Fourlanos S. Fulcher G. Hamlyn J. Haywood C. Hocking S. Huchinson M. Jeffries W. Kyl M. Lo C. Mah P.M. Makepeace A. Marope D. Nanayakkar N. Nankervis A. Palmer N. Palolus B. Pillai S. Price S. Price S. Proietto J. Reutens A. Rodrigo N. Sheikh A. Smith G. So M. Soldatos G. Stuckey B. Sumithran P. Teede H. Vora P. Williams L. Abib E. Adão Poço C. Alves É.F. Andreatta Bernardi Barea J. Avezum Oliveira L. Castro D.L.C. Correa da Cruz I. Costa M. Cruz I. Cunha S. Da Silva M.A.V. de Carvalho Camara Bona R. de Paula B. Eliaschewitz F. Fazolli G. Ferreira Filho C.A. Fortes J. França C. Franco D.R. Genestreti P.R. Giorgeto F. Gonçalves R.M. Grossman M.E. Henrique Marcelino A.C. Hernandes M. Horta A. Jaeger C. Kaneblai M. Kauffman Rutenberg C. Kerr Saraiva J.F. Lemos M.A. Maia L. Manenti E.R. Marques M. Melissa Valerio C. Moreira R. Mothé F. Mouco O.M. Moura P. Moura Jorge J.C. Nakashima C. Nakazone M. Napoli T. Nunes C. Nunes Salles J.E. Oliveira K. Oliveira M. Pantano G.S. Petri F. Piazza L. Pires A.C. Pizzato P. Prata S. Precoma D. Rech R. Reis G. Reis H. Resende E. Ribas Fortes J. Rodovalho S. Rossi dos Santos F. Salles J.E. Sampaio C.R. Santos T. Santos dos Santos V. Silva e Quadros T. Silveira D. Siqueira K.N. Teireira M. Uehara M. Valerio C. Vianna H. Vidotti M.H. Visconti G.L. Zanella M.T. Andreeva V. Borisov R. Botushanov N. Dimitrov G. Dimova K. Dragoychev T. Grigorova V. Gushterova V. Ivanov I. Kocelova T. Kurktschiev D. Miletieva M. Nenkova-Gugusheva N. Pancheva R. Pavlova M. Raev D. Spasova V. Stoikov A. Troev D. Yanev T. Yoncheva-Mihaylova M. Abitbol A. Ajala B. Alguwaihes A. Ardilouze J-L. Aris-Jilwan N. Arnaout A. Aronson R. Aslam N. Babin S. Bailargeon J-P. Bailey A. Bajaj H. Beauchesne C. Beca S. Belanger A. Bell A. Bellabarba D. Berard L. Berenbaum B. Bergeron V. Berlingieri J. Bernier F. Bishara P. Blank D. Blumer I. Brault S. Breton D. Carpentier A. Cha J. Chandra P. Chiasson J-L. Conway J.R. Couture G. Couture N. Dagenais G. Datta D. D’Ignazio G. Dumas R. Fay D. Frechette A. Frenette L. Fung D. Gagnon N. Galter M. Garon J. Gauthier J.S. Geadah C. Gilbert J. Girard R. Goldenberg R. Grossman L.D. Gupta N. Halle J-P. Hivert M-F. Houde G. Houlden R. Hramiak I. Jablonski T. Jain A.J. Khandwala H. Khosla M. Lachance C. Laflamme E. Langlois M-F. Larivee L. Liutkus J. Lochnan H. Malik S. McDonald C. Mehta P. Mihailidis J. Milot A. Narula P. Nault P. Nayar A. Nisker W. Ouellet G. Palardy J. Patel M. Paul T. Pedersen S. Perron P. Pesant M-H. Poirier P. Poulin M-C. Punthakee Z. Rehman W. Ross S. Sagar P. Saliba N. Sandler S. Schiffrin A. Schlosser R. Seth-Sharma A. Sherman M. Sionit D. Sivakumar T. Soto J. St-Amour E. Steen O. Sussman J. Telner A. Tobe S. Twum-Barima D-Y. Van Zanten A. VanRossum N. Vecchiarelli J. Ward R. Wessengel J. Weisnagel S. Wilderman I. Woo V. Yakubovich N. Yale J-F. Yared Z. Acevedo M. Aguirre M.L. Aizman A. Barroso M.S. Cobos L. Danin Vargas A. Descalzi B. Godoy G. Grumberg E. Lahsen R. Larenas G. Ortiz E. Paredes J. Potthoff S. Retamal E. Rojas L. Salgado M. Santibanez C. Solis C. Stokins B. Accini J. Acebedo J. Agudelo Baena L.M. Alarcon S. Angel J. Arcos E. Aroca Martinez M. Atuesta L. Balaguera J. Ballestas D. Barrera S.I. Barrios Reyes R. Bayona A. Bermudez A. Bernal D.Z. Blanquicett M. Bravo V. Bueno W. Burbano Delgado A. Cadena A. Cadena A. Caicedo S. Celemin C. Consuegra R. Contreras Pimienta C. Corredor K.J. Cure C. De La Hoz Rueda L.D. Delgado E. Diaz S. Diego M. Donado A. Encinales Sanabria W. Escobar J. Escorcia G. Forero L. Fuentes L. Garcia M. Garcia Lozada H. Garcia Ortiz L. Giraldo A. Gomez Gonzalez L. Granada J. Gutierrez C. Henao N. Hernandez E. Herrera Uejbe O.M. Higuera Cobos J.D. Ibarra Gómez J. Jaimes E.H. Jaramillo M. Jaramillo N. Jaramillo Gomez C. Jaramillo Sanchez M. Jarava Durán I. Lopez Ceballos C. Madrid C. María Amastha E. Mercado J. Molina D.I. Molina Soto J. Montoya C. Morales A. Muñoz C. Orozco L.A. Osorio O. Palmera Sanchez J.M. Peña A. Perez J. Perez Agudelo J. Pérez Amador G. Pertuz C. Posada I. Puerta C. Quintero A. Quiroz D. Rendon C. Reyes A. Reyes A. Ripoll D. Rivera C. Rocha M. Rodriguez J.F. Rodriguez Villanueva K.A. Rodriguez Zabala J.E. Rojas S. Romero M. Rosero R. Rosillo Cardenas A.R. Rueda L. Sanchez G. Sanchez T. Sotomayor Herazo A. Suarez M. Torres M. Trujillo F. Urina M. Van Strahlen L. Velandia C. Velasquez Guzman C. Velazquez E. Vidal Prada T. Yepez Alvaran J.P. Zarate D. Andelova J. Benesova R. Buzova B. Cech V. Chodova I. Choura M. Dufka A. Gamova A. Gorgol J. Hala T. Havlova H. Hlavkova D. Horanska P. Ilcisin-Valova J. Jenickova P. Jerabek O. Kantorova I. Kolomaznikova K. Kopeckova I. Kopeckova M. Linhart K. Linhart T. Malecha J. Malicherova E. Neubauerova D. Oznerova M. Partys R. Pederzoliova E. Petrusova M. Prymkova V. Racicka E. Reissova I. Roderova E. Stanek L. Striova A. Svarcova D. Svoboda P. Szeghy Malicharova E. Urge J. Vesely L. Wasserburger B. Wasserburgerova H. Zahumensky E. Zamrazil V. Alawi H. Anastasiadis E. Axthelm E. Bieler T. Buhrig C. Degtyareva E. Dellanna F. Derwahl K-M. Diessel S. Dogiami B. Dorn-Weitzel K. Ernst M. Faulmann G. Fetscher B. Forst T. Freyer-Lahres G. Funke K. Ganz X. Gleixner C. Hanefeld C. Heinrichs S. Helleberg S. Henkel E. Hetzel G.R. Hoffmann C. Jacob F. Jacob S. John F. Jonczyk A. Kamke W. Klein C. Kleinhardt M. Kleophas W. Kosch C. Kreutzmann K. Kühn A. Lee-Barkey Y.H. Lier A. Maatouk S. Minnich J. Mitry M. Muessig I. Nicula D. Niemann M. Nothroff J. Ott P. Pfuetzner A. Pfützner A. Pistrosch F. Pohl W. Prochazkova Z. Retkowska M. Rosin H. Sachsenheimer D. Samer H. Sanuri M. Schaefer A. Schaper F. Schulze E-D. Schulze M. Schumann M. Segiet T. Sowa V. Stahl H-D. Steinfeldt F. Teige M. Trieb B. Tschoepe D. Uebel P. Warken B. Weigmann I. Weyland K. Wilhelm K. Balo T. Balsay M. Bende I. Bezzegh K. Birkus Z. Buday B. Csomai M. Deak L. Dezso E. Faludi P. Faluvegi M. Fazekas I. Feher A. Fejer C. Finta E. Fulcz A. Gaal Z. Gurzo M. Hati K. Herczeg G. Jozsef I. Juhasz M. Keltai K. Koranyi L. Kulcsar E. Kun K. Laczko A. Literáti-Nagy B. Mezo I. Mileder M. Moricz I. Nagy K. Nagybaczoni B. Nemeth C. Oze A. Pauer J. Peterfai E. Polocsanyi B. Poor F. Reiber I. Salamon C. Sebestyen J. Torok I. Tuu M. Varga A. Vass V. Ahn C.M. Ahn C. ByungWon P. Chang H-J. Chang K. Choi E-Y. Choi H.S. Chung J-W. Hong B-K. Hong Y.J. Hyon M.S. Jeong M.H. Kang S. Kim B-K. Kim J-H. Kim J.H. Kim K-S. Kim K-S. Kim M.H. Kim P-J. Kim S-K. Kim Y-S. Kim Y.K. Koh Y.S. Kwon H.M. Lee B.K. Lee B-W. Lee J.B. Lee M-M. Lim Y-M. Min P.K. Park J.S. Park J. Park K.H. Park S. Pyun W.B. Rim S.J. Ryu D-R. Seo H-S. Seung K.B. Shin D-H. Sim D.S. Yoon Y.W. Andersone I. Babicka K. Balcere I. Barons R. Capkovska I. Geldnere K. Grigane I. Jegere B. Lagzdina I. Mora L. Pastare S. Ritenberga R. Romanova J. Saknite I. Sidlovska N. Sokolova J. Steina S. Strizko I. Teterovska D. Vizina B. Barsiene L. Belozariene G. Daugintyte-Petrusiene L. Drungiliene N. Garsviene N. Grigiene A. Grizas V. Jociene V. Kalvaitiene D. Kaupiene J. Kavaliauskiene J. Kozloviene D. Lapteva I. Maneikiene B. Marcinkeviciene J. Markauskiene V. Meiluniene S. Norkus A. Norviliene R. Petrenko V. Radzeviciene R. Sakalyte G. Urbonas G. Urbutiene S. Vasiliauskas D. Velickiene D. Aguilar C. Alcocer M. Avalos-Ramirez J.A. Banda-Elizondo R. Bricio-Ramirez R. Cardenas Mejia K. Cavazos F. Chapa J. Cienfuegos E. De la Peña A. de la Peña Topete G. De los Rios Ibarra M.O. Elias D. Flores-Moreno C. Garcia Hernandez P. Gonzalez L.G. Guerra Moya R.L. Guerra-Lopez A. Hernandez Baylon R. Herrera Colorado C. Herrera-Marmolejo M. Islas-Palacios N. Lopez E. Lopez F. Lopez Alvarado A. Luna Ceballos R.I. Morales Villegas E. Moreno-Virgen G. Parra Perez R.L. Pascoe Gonzalez S. Peralta-Cantu I. Previn R. Ramirez R. Ramirez R. Ramos Zavala M.G. Rodriguez M. Salgado-Sedano R. Sanchez-Aguilar A.C. Santa Rosa Franco E. Sauque-Reyna L. Suarez Otero R. Torres I. Velarde-Harnandez E. Villagordoa J. Villeda-Espinoza E. Vital-Lopez J. Zavala- Bello C.J. Baker J. Barrington-Ward E. Brownless T. Carroll R. Carson S. Choe M. Corin A. Corley B. Cutfield R. Dalaman N. Dixon P. Drury P. Dyson K. Florkowski C. Ford M. Frengley W. Helm C. Katzen C. Kerr J. Khanolkar M. Kim D. Koops R. Krebs J. Leikis R. Low K. Luckey A. Luke R. Macaulay S. Marks R. McNamara C. Millar-Coote D. Miller S. Mottershead N. Reid J. Robertson N. Rosen I. Rowe D. Schmiedel O. Scott R. Sebastian J. Sheahan D. Stiebel V. Ternouth I. Tofield C. Venter D. Williams M. Williams M. Wu F. Young S. Arciszewska M. Bochenek A. Borkowski P. Borowy P. Chrzanowski T. Czerwinski E. Dwojak M. Grodzicka A. Janiec I. Jaruga J. Jazwinska-Tarnawska E.K. Jedynasty K. Juzwiak-Czapiewska D. Karczewicz-Janowska J. Konieczny J. Konieczny M. Korol M. Kozina M. Krzyzagorska E. Kucharczyk-Petryka E. Laz R. Majchrzak A. Mrozowska Z. Mularczyk M. Nowacka E. Peczynska J. Petryka R. Pietrzak R. Pisarczyk-Wiza D. Rozanska A. Ruzga Z. Rzeszotarska E. Sacha M. Sekulska M. Sidorowicz-Bialynicka A. Stasinska T. Strzelecka-Sosik A. Swierszcz T. Szymkowiak K.M. Turowska O. Wisniewska K. Wiza M. Wozniak I. Zelazowska K. Ziolkowska-Gawron B. Zytkiewicz-Jaruga D. Albota A. Alexandru C. Avram R. Bala C. Barbonta D. Barbu R. Braicu D. Calutiu N. Catrinoiu D. Cerghizan A. Ciorba A. Craciun A. Doros R. Duma L. Dumitrache A. Ferariu I. Ferician Moza A. Ghergan A. Ghise G. Graur M. Gribovschi M. Mihai B. Mihalache L. Mihalcea M. Mindrescu N. Morosanu M. Morosoanu A. Mota M. Moza A. Nafornita V. Natea N. Nicodim S. Nita C. Onaca A. Onaca M. Pop C. Pop L. Popa A. Popescu A. Pruna L. Roman G. Rosu M. Sima A. Sipciu D. Sitterli-Natea C.N. Szilagyi I. Tapurica M. Tase A. Tutescu A-C. Vanghelie L. Verde I. Vlad A. Zarnescu M. Akhmetov R. Allenova I. Avdeeva I. Baturina O. Biserova I. Bokovin N. Bondar I. Burova N. Chufeneva G. Chumachek E. Demidova M. Demin A. Drobysheva V. Egorova I. Esenyan L. Gelig E. Gilyarevsky S. Golshmid M. Goncharov A. Gorbunova A. Gordeev I. Gorelysheva V. Goryunova T. Grebenshchikova I. Ilchenko R. Ivannikova M. Karabalieva S. Karpeeva J. Khaykina E. Kobalava Z. Kononenko I. Korolik O. Korshunova A. Kostenko V. Krasnopevtseva I. Krylova L. Kulkova P. Kuzmina I. Ledyaeva A. Levashov S. Lokhovinina N. Lvov V. Martirosyan N. Nedogoda S. Nilk R. Osmolovskaya Y. Panov A. Paramonova O. Pavlova E. Pekareva E. Petunina N. Ponamareva S. Reshedko G. Salasyuk A. Sepkhanyan M. Serebrov A. Shabelnikova O. Skvortsov A. Smirnova O. Spiridonova O. Strogova S. Taratukhin E. Tereschenko S. Trukhina L. Tsarkova O. Tsoma V. Tumarov F. Tyan N. Tyurina T. Villevalde S. Yankovaya E. Zarutskaya L. Zenkova E. Badat A. Bester F. Blignaut S. Blom D. Booysen S. Boyd W. Brice B. Brown S. Burgess L. Cawood R. Coetzee K. Conradie H. Cronje T. de Jong D. Ellis G. Emanuel S. Engelbrecht I. Foulkes S. Fourie D. Gibson G. Govender T. Hansa S. Hemus A.C. Hendricks F. Heradien M. Holmgren C. Hoosain Z. Horak E. Howard J. Immink I. Janari E. Jivan D. Klusmann K. Labuschagne W. Lai Y. Latiff G. Lombaard J. Lottering H. Meeding R. Middlemost S. Mitha H. Mitha I. Mkhwanazi S. Moodley R. Murray A. Musungaie D. Osman Y. Peacey K. Pillay-Ramaya L. Pretorius C. Prozesky H. Sarvan M. Scholtz E. Sebesteny A. Skinner B. Skriker M. Smit M. Stapelberg A-M. Swanepoel N. Urbach D. van Aswegen D. van Zyl F. Van Zyl L. Venter E. Wadvalla S. Wing J. Wolmarans K. Abreu C. Aguilà P. Aguilera E. Alonso N. Alvarez C. Cajas P. Castro J.C. Codinachs R. Contreras J. Coves M.J. Fajardo C. Ferrer J.C. Font N. Garcia M. Gil M.A. Gomez F. Gomez L.A. Gonzalbez J. Griera J.L. Masmiquel L. Mauricio D. Narejos Perez S. Nicolau J.A. Noheda Contreras O. Olivan J. Olivares J. Ortega E. Pellitero S. Pertusa S. Rius F. Rodriguez I. Sánchez-Juan C. Santos D. Soldevila B. Subias D. Terns M. Trescoli C. Vilaplana J. Villanueva A. Albo J. Antus K. Axelsson M. Bergström L. Binsell-Gerdin E. Boman K. Botond F. Dotevall A. Graipe A. Jarnet C. Kaminska J. Kempe A. Korhonen M. Linderfalk C. Liu B. Ljungstroem K. Ljungström K. Malmqvist L. Mellbin L. Mooe T. Nicol P. Norrby A. Ohlsson A. Rosengren A. Saaf J. Salmonsson S. Strandberg O. Svensson K-A. Tengmark B-O. Tsatsaris G. Ulvenstam A. Vasko P. Chang C-T. Chang H-M. Chen J-F. Chen T-P. Chung M-M. Fu C-P. Hsia T-L. Hua S-C. Kuo M-C. Lee C. Lee I-T. Liang K-W. Lin S.Y. Lu C-H. Ma W-Y. Pei D. Shen F-C. Su C-C. Su S-W. Tai T-S. Tsai W-N. Tsai Y-T. Tung S-C. Wang J-S. Yu H-I. Al-Qaissi A. Arutchelvam V. Atkin S. Au S. Aye M.M. Bain S. Bejnariu C. Bell P. Bhatnagar D. Bilous R. Black N. Brennan U. Brett B. Bujanova J. Chow E. Collier A. Combe A. Courtney C. Courtney H. Crothers J. Eavis P. Elliott J. Febbraro S. Finlayson J. Gandhi R. Gillings S. Hamling J. Harper R. Harris T. Hassan K. Heller S. Jane A. Javed Z. Johnson T. Jones S. Kennedy A. Kerr D. Kilgallon B. Konya J. Lindsay J. Lomova-Williams L. Looker H. MacFarlane D. Macrury S. Malik I. McCrimmon R. McKeith D. McKnight J. Mishra B. Mukhtar R. Mulligan C. O’Kane M. Olateju T. Orpen I. Richardson T. Rooney D. Ross S.B. Sathyapalan T. Siddaramaiah N. Sit L.E. Stephens J. Turtle F. Wakil A. Walkinshaw E. Ali A. Anderson R. Arakaki R. Aref O. Ariani M.K. Arkin D. Banarer S. Barchini G. Bhan A. Branch K. Brautigam D. Brietzke S. Brinas M. Brito Y. Carter C. Casagni K. Casula S. Chakko S. Charatz S. Childress D. Chow L. Chustecka M. Clarke S. Cohen L. Collins B. Colon Vega G. Comulada-Rivera A. Cortes-Maisonet G. Davis M. de Souza J. Desouza C. Dinnan M. Duffy-Hidalgo B. Dunn B. Dunn J. Elman M. Felicetta J. Finkelstein S. Fitz-Patrick D. Florez H. Forker A. Fowler W. Fredrickson S. Freedman Z. Gainey Narron B. Gainey-Ferree K. Gardner M. Gastelum C. Giddings S. Gillespie E. Gimness M.P. Goldstein G. Gomes M. Gomez N. Gorman T. Goswami K. Graves A. Hacking S. Hall C. Hanson L. Harman S. Heber D. Henry R. Hiner J. Hirsch I. Hollander P. Hooker T. Horowitz B. Hoste L. Huang L. Huynh M. Hyman D. Idriss S. Iranmanesh A. Karounos D. Kashyap M. Katz L. Kaye W. Khaiton Y. Khardori R. Kitchen T. Klein A. Knffem W. Kosiborod M. Kreglinger N. Kruger D. Kumar A. Laboy I. Larrabee P. Larrick L. Lawson D. Ledet M. Lenhard J. Levy J. Li G. Li Z. Lieb D. Limcolioc A. Lions-Patterson J. Lorber D. Lorch D. Lorrello M. Lu P. Lucas K.J. Ma S-L. MacAdams M. Magee M. Magno A. Mahakala A.R. Marks J. McCall A. McClanahan W. Jr McClary C. Melendez L. Melish J. Michaud D. Miller C. Miller N. Mora P. Moten M. Mudaliar S. Myrick G. Narayan P. Nassif M. Neri K. Newton T. Niblack P. Nicol P. Nyenwe E. Odugbesan A.O. Okorocha Y. Ortiz Carrasquillo R. Osei K. Palermo C. Patel H. Patel K. Pau C. Perley M. Plevin S. Plummer E. Powell R. Qintar M. Rawls R. Reyes-Castano J. Reynolds L. Richards R. Rosenstock J. Rowe C. Saleh J. Sam S. Sanchez A. Sander D. Sanderson B. Savin V. Seaquist E. Shah J. Shi S. Shivaswamy V. Shlotzhauer T. Shore D. Skukowski B. Soe K. Solheim V. Soufer J. Steinberg H. Steinsapir J. Tarkington P. Thayer D. Thomson S. Thrasher J. Tibaldi J. Tjaden J. Tores O. Trence D. Trikudanathan S. Ullal J. Uwaifo G. Vo A. Vu K. Walia D. Weiland K. Whitehouse F. Wiegmann T. Wyne K. Wynne A. Yuen K. Zaretzky J. Zebrack J. Zieve F. Zigrang W. REWIND Investigators Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019 394 10193 131 138 10.1016/S0140‑6736(19)31150‑X 31189509
    [Google Scholar]
  150. Mann J.F.E. Ørsted D.D. Brown-Frandsen K. Marso S.P. Poulter N.R. Rasmussen S. Tornøe K. Zinman B. Buse J.B. LEADER Steering Committee and Investigators Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 2017 377 9 839 848 10.1056/NEJMoa1616011 28854085
    [Google Scholar]
  151. Persson F. Bain S.C. Mosenzon O. Heerspink H.J.L. Mann J.F.E. Pratley R. Raz I. Idorn T. Rasmussen S. von Scholten B.J. Rossing P. LEADER Trial Investigators Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: A post hoc analysis of the LEADER trial. Diabetes Care 2021 44 4 1020 1026 10.2337/dc20‑1622 33504496
    [Google Scholar]
  152. Mann J.F.E. Hansen T. Idorn T. Leiter L.A. Marso S.P. Rossing P. Seufert J. Tadayon S. Vilsbøll T. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020 8 11 880 893 10.1016/S2213‑8587(20)30313‑2 32971040
    [Google Scholar]
  153. Heerspink H.J.L. Apperloo E. Davies M. Dicker D. Kandler K. Rosenstock J. Sørrig R. Lawson J. Zeuthen N. Cherney D. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials. Diabetes Care 2023 46 4 801 810 10.2337/dc22‑1889 36801984
    [Google Scholar]
  154. Lincoff A.M. Brown-Frandsen K. Colhoun H.M. Deanfield J. Emerson S.S. Esbjerg S. Hardt-Lindberg S. Hovingh G.K. Kahn S.E. Kushner R.F. Lingvay I. Oral T.K. Michelsen M.M. Plutzky J. Tornøe C.W. Ryan D.H. SELECT Trial Investigators Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 2023 389 24 2221 2232 10.1056/NEJMoa2307563 37952131
    [Google Scholar]
  155. Colhoun H.M. Lingvay I Brown P.M. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024 30 7 2058 2066 10.1038/s41591‑024‑03015‑5
    [Google Scholar]
  156. Heerspink H. Tuttle K. Pavo I. Haupt A. Yang Z. Wiese R. Hemmingway A. Cherney D. Sattar N. Longuet C. Tirzepatide reduces albuminuria in patients with type 2 diabetes: Post hoc pooled analysis of surpass-1 to -5. Can. J. Cardiol. 2023 39 10 S144 10.1016/j.cjca.2023.06.231
    [Google Scholar]
  157. Mahfoud F. Cremers B. Janker J. Link B. Vonend O. Ukena C. Linz D. Schmieder R. Rump L.C. Kindermann I. Sobotka P.A. Krum H. Scheller B. Schlaich M. Laufs U. Böhm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012 60 2 419 424 10.1161/HYPERTENSIONAHA.112.193870 22733462
    [Google Scholar]
  158. Ott C. Mahfoud F. Schmid A. Ditting T. Veelken R. Ewen S. Ukena C. Uder M. Böhm M. Schmieder R.E. Improvement of albuminuria after renal denervation. Int. J. Cardiol. 2014 173 2 311 315 10.1016/j.ijcard.2014.03.017 24681017
    [Google Scholar]
  159. Zhang Z.H. Yang K. Jiang F.L. Zeng L.X. Jiang W.H. Wang X.Y. The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension. J. Clin. Hypertens. (Greenwich) 2014 16 8 599 605 10.1111/jch.12367 25039997
    [Google Scholar]
  160. Kiuchi M.G. Graciano M.L. Carreira M.A.M.Q. Kiuchi T. Chen S. Lugon J.R. Long-Term Effects of Renal Sympathetic Denervation on Hypertensive Patients With Mild to Moderate Chronic Kidney Disease. J. Clin. Hypertens. (Greenwich) 2016 18 3 190 196 10.1111/jch.12724 26718019
    [Google Scholar]
  161. Verloop W.L. Vink E.E. Spiering W. Blankestijn P.J. Doevendans P.A. Bots M.L. Vonken E. Voskuil M. Leiner T. Effects of renal denervation on end organ damage in hypertensive patients. Eur. J. Prev. Cardiol. 2015 22 5 558 567 10.1177/2047487314556003 25326543
    [Google Scholar]
  162. Prasad B. Berry W. Goyal K. Dehghani P. Townsend R.R. Central blood pressure and pulse wave velocity changes post renal denervation in patients with stages 3 and 4 chronic kidney disease: The regina RDN study. Can. J. Kidney Health Dis. 2019 6 2054358119828388 10.1177/2054358119828388 30792873
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673348953250310044927
Loading
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Bentham Science Publishers ; https://doi.org/10.2174/0109298673348953250310044927
/content/journals/cmc/10.2174/0109298673348953250310044927
/content/journals/cmc/10.2174/0109298673348953250310044927
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: predictive medicine ; kidney ; microalbuminuria ; pharmacotherapy ; endothelium ; Hypertension

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test